

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number  
WO 2005/040151 A1

(51) International Patent Classification<sup>7</sup>: C07D 401/04, 401/14, 409/14, 405/14, A61K 31/4965

(74) Agent: TABUSHI, EIJI; c/o Fujisawa Pharmaceutical Co., Ltd., Osaki Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaki-shi, OSAKA 532-8514 (JP).

(21) International Application Number:

PCT/JP2004/016193

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 25 October 2004 (25.10.2004)

English

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2003905895 27 October 2003 (27.10.2003) AU  
2004902764 24 May 2004 (24.05.2004) AU

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and


(75) Inventors/Applicants (for US only): YONISHI, Satoshi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). AOKI, Satoshi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). MATSUSHIMA, Yuji [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). AKAHANE, Atsushi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF



(57) Abstract: A pyrazine derivative of the following formula (I) or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke), etc., heart failure and the like.

WO 2005/040151 A1

## DESCRIPTION

## PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF

## TECHNICAL FIELD

The present invention relates to a novel pyrazine derivative and a salt thereof, which are useful as medicaments.


## BACKGROUND ART

Adenosine is a ubiquitous biochemical messenger. Adenosine binds to and activates seven-transmembrane spanning G-protein coupled receptors, eliciting a variety of physiological responses. Adenosine receptors are divided into four known subtypes (i.e., A<sub>1</sub>, A<sub>2a</sub>, A<sub>2b</sub>, and A<sub>3</sub>). These receptor subtypes mediate different, and sometimes opposing, effects. Activation of the adenosine A<sub>1</sub> receptor, for example, elicits an increase in renal vascular resistance, while activation of the adenosine A<sub>2a</sub> receptor elicits a decrease in renal vascular resistance. Accordingly, adenosine antagonists are useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.

Some 2-aminopyridine compounds to exhibit adenosine receptor antagonism are known (WO 02/14282, WO 01/25210,

etc.), and some 2-aminopyrimidine compounds are also known (US 2001/0027196, etc.).

However, it is generally difficult to produce a pyrazine which is substituted by four different 5 substituents, and for example the synthesis of a pyrazine compound of the formula A :



10 wherein Ar and Ar' are independently same or different aryl; and

R, R' and M are independently hydrogen or suitable substituent;

is reported (e.g. (1) *J. Org. Chem.*, 40, 2341 (1975)., (2) *J. 15 Heterocyclic Chem.*, 15, 665 (1978), (3) *J. Chem. Soc., Perkin Trans. 1*, 885 (1994)., (4) *Synthesis*, 931 (1994)., (5) WO-02/088084, etc.), however the Ar and Ar' thereof are same, and the selective synthesis of a pyrazine compound A wherein Ar and Ar' are different is not shown as far as 20 we know, and 2-amino-6-aryl-5-(6-oxo-1,6-dihydro-pyrid-3-yl)-pyrazine compounds and derivatives thereof are novel, so there has been no knowledge about these compounds, so far. In addition, any pyrazine derivatives having both of adenosine A<sub>1</sub> and A<sub>2a</sub> inhibitory 25 activities are not known.

## DISCLOSURE OF INVENTION

The present invention relates to a novel pyrazine derivative and a pharmaceutically acceptable salt thereof, which are useful as medicaments with no or less toxicity (particularly the convulsive toxicity); processes for preparing the preparation of pyrazine derivative and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazine derivative or a pharmaceutically acceptable salt thereof; a use of said pyrazine derivative or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazine derivative or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said pyrazine derivative or a pharmaceutically acceptable salt thereof to a human being or an animal.

The pyrazine derivatives and a salt thereof are adenosine antagonists (especially, A<sub>1</sub> receptor and A<sub>2</sub> (particularly A<sub>2a</sub>) receptor dual antagonists) and possess various pharmacological actions such as anticonvulsant action, cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective action, cardiotonic action, vasodilating action (e.g. cerebral vasodilating action, etc.), the action of increasing the renal blood flow, renal protective

action, improvement action of renal function, enhancing action of lipolysis, inhibition action of anaphylactic bronchoconstriction, acceleration action of the insulin release, the action of increasing the production of 5 erythropoietin, inhibiting action of platelet aggregation, or the like.

They are useful as cognitive enhancer, antianxiety drug, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of 10 cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, antihypertensive agent, drug for renal failure (renal insufficiency), drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, antiobesity, 15 antiasthmatic, bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere's syndrome, drug for anemia; 20 drug for thrombosis, drug for myocardial infarction, drug for obstruction, drug for arteriosclerosis obliterans, drug for thrombophlebitis, drug for cerebral infarction, drug for transient ischemic attack, drug for angina pectoris, or the like; and useful for the prevention and/or 25 treatment of depression, dementia (e.g. Alzheimer's

disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure; hypertension (e.g. essential hypertension,

5 nephrogenous hypertension, etc.); circulatory insufficiency (acute circulatory insufficiency) caused by, for example, ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral

10 ischemia/reperfusion injury, etc.), shock (e.g. endotoxin shock, hemorrhagic shock, etc.), surgical procedure, or the like; post-resuscitation asystole; bradyarrhythmia; electro-mechanical dissociation; hemodynamic collapse; SIRS (systemic inflammatory response syndrome); multiple

15 organ failure; renal failure (renal insufficiency) (e.g. acute renal failure, etc.), renal toxicity [e.g. renal toxicity induced by a drug such as cisplatin, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc.], nephrosis,

20 nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.); obesity, bronchial asthma, gout, hyperuricemia, sudden infant death


25 syndrome, immunosuppression, diabetes, ulcer such as

peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc.),  
 pancreatitis, Meniere's syndrome, anemia,  
 dialysis-induced hypotension, constipation, ischemic  
 bowel disease, ileus (e.g. mechanical ileus, adynamic ileus,  
 5 etc.); and myocardial infarction, thrombosis (e.g.  
 arterial thrombosis, cerebral thrombosis, etc.),  
 obstruction, arteriosclerosis obliterans,  
 thrombophlebitis, cerebral infarction, transient ischemic  
 attack, angina pectoris, or the like.

10


The novel pyrazine derivative or a salt thereof of  
 the present invention can be shown by the following formula  
 (I):

15



wherein

20



wherein

25

$R^6$  is hydrogen, or optionally substituted lower  
 alkyl;

$R^7$  is hydrogen or halogen;

$R^8$  is lower alkyl;

$R^2$  is hydrogen; hydroxy; halogen; cyano; or lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by substituent(s);


5  $R^3$  and  $R^4$  are independently hydrogen, lower alkyl or acyl; and

$R^5$  is lower alkyl, lower alkenyl, lower alkynyl, cyano, aryl or heterocyclic group, each of which is 10 optionally substituted by substituent(s);

or a salt thereof.

The preferred embodiments of the pyrazine compound of the present invention represented by the general formula 15 (I) are as follows.

(1) The pyrazine compound of the general formula (I) wherein



wherein

$R^6$  is hydrogen, lower alkyl, aryl(lower)alkyl,

heteroaryl(lower)alkyl;

$R^7$  is hydrogen or halogen;

25  $R^2$  is hydrogen, halogen, cyano, optionally substituted

lower alkyl, optionally substituted lower alkynyl,  
lower alkoxy, aryloxy, arylthio, carbamoyl,  
carboxy, protected carboxy or optionally  
substituted amino;

5      R<sup>3</sup> and R<sup>4</sup> are independently hydrogen or lower alkyl;  
and

R<sup>5</sup> is aryl or heteroaryl each of which is optionally  
substituted by one or more substituent(s);  
or a salt thereof.

10     (2) The pyrazine compound of (1) above  
wherein

R<sup>2</sup> is hydrogen, halogen, cyano,  
hydroxylated(lower)alkyl, lower alkynyl, lower  
alkoxy, aryloxy, arylthio, carboxy, esterified  
15     carboxy, carbamoyl, amidated carboxy, amino or  
mono- or di-(lower)alkylamino;

R<sup>3</sup> and R<sup>4</sup> are independently hydrogen;

R<sup>5</sup> is aryl or heteroaryl, each of which is optionally  
substituted by one or more substituent(s) selected

20     from the group consisting of halogen and lower  
alkoxy;

R<sup>6</sup> is hydrogen or lower alkyl; and

R<sup>7</sup> is hydrogen;  
or a salt thereof.

25     (3) The pyrazine compound of (2) above

wherein

R<sup>2</sup> is hydrogen, bromo, cyano, hydroxymethyl, hydroxyethyl, hydroxypropyl, ethynyl, methoxy, ethoxy, propoxy, phényloxy, phenylthio, carboxy, carbamoyl, mono- or di-methylaminocarbonyl, pyridylmethylaminocarbonyl, hydroxymethylaminocarbonyl or mono- or di-methylamino;

R<sup>3</sup> and R<sup>4</sup> are independently hydrogen;

R<sup>5</sup> is phenyl, pyridyl, furyl, thienyl, pyrrolyl or pyrazolyl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of fluoro, chloro and methoxy;

R<sup>6</sup> is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl ; and

R<sup>7</sup> is hydrogen;

or a salt thereof.

(4) The pyrazine compound of (3) above

wherein

R<sup>2</sup> is hydrogen, cyano, ethynyl, methoxy, phényloxy, phenylthio, carboxy, carbamoyl or methylamino; and

R<sup>5</sup> is phenyl, furyl or thienyl, each of which is optionally substituted by one or more

substituent(s) selected from the group consisting

of fluoro, chloro and methoxy;  
or a salt thereof.

(5) The pyrazine compound of (4) above

wherein

5      R<sup>2</sup> is hydrogen, cyano, carboxy, carbamoyl or  
methylamino;


R<sup>5</sup> is phenyl which is optionally substituted by one or  
more fluoro; and

R<sup>6</sup> is hydrogen, methyl, ethyl or isopropyl;

10     or a salt thereof.


The object compound (I) and a salt thereof of the present invention can be prepared by the following processes.

15     Process 1




20     or a salt thereof     or a salt thereof     or a salt thereof


Process 2




### Process 3




#### Process 4





## Process 5



### Process 6



Process 7Process 8

[wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>8</sup> are each as defined above;  
 R<sup>9</sup> is cyano, carbamoyl or carboxy;  
 R<sup>10</sup> is optionally substituted lower alkyl;  
 20 R<sup>11</sup> and R<sup>12</sup> are independently hydrogen, lower alkyl, lower alkoxy or cyclo(lower)alkyl, each of which is optionally substituted by substituent(s); or R<sup>11</sup> and R<sup>12</sup>, together with the nitrogen atom to which they are attached, represent a optionally substituted N-containing heterocyclic group;  
 25 R<sup>13</sup> is lower alkyl, lower alkenyl, lower alkynyl,

lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by substituent(s);

Y is a leaving group;

5 Hal is a halogen atom; and

Z is hydrogen, an alkali metal (e.g. lithium, sodium, potassium, etc.),  $\text{SnBu}_3$ ,  $\text{BW}_2$  or Met-Hal;

wherein  $\text{BW}_2$  is a part of organoboron compound such as

$\text{B}(\text{OH})_2$ ,  $\text{B}(\text{CHCH}_3\text{CH}(\text{CH}_3)_2)_2$ ,

10 tetramethyl-1,3,2-dioxaborolan-2-yl,

9-borabicyclo[3.3.1]nonanyl, or the like;


and


Met-Hal is a part of metalhalide compound such as  $\text{MgBr}$ ,  $\text{ZnCl}$ , or the like. ]

15

The starting compounds or a salt thereof can be prepared, for example, by the following reaction schemes.

Process A




Process B

(IX)

(X)

(XI)

5 or a salt thereof or a salt thereof or a salt thereof

Process C


10

(XI)

(XIII)

or a salt thereof

or a salt thereof

Process D


(XIII)

(XIV)

20

or a salt thereof

or a salt thereof

Process E

25

(XV)

(XVI)

(II)

or a salt thereof

or a salt thereof

or a salt thereof

30 [wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>10</sup>, Y and Hal are each as defined

above.]

In addition to the processes as mentioned above, the object compound (I) and a salt thereof can be prepared, for 5 example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.

The starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations 10 in the present specification or in a manner similar thereto.

The object compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples, or in a manner similar thereto.

It is also to be noted that the solvating form of the 15 compound (I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.

It is also to be noted that radiolabelled derivatives of the compound (I), which are suitable for biological 20 studies, are included within the scope of the present invention.

Suitable salts of the object compound (I) are conventional pharmaceutically acceptable ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, 25 potassium salt, etc.) and an alkaline earth metal salt (e.g.

calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. arginine, 10 aspartic acid, glutamic acid, etc.), and the like.

Suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof and which appear in the above and following description in the present specification are explained in 15 detail as follows.

The term "optionally substituted" refers to "unsubstituted or substituted".

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

20 Suitable "lower alkyl" and "(lower)alkyl" moiety in the term of "mono- or di-(lower)alkylamino" may include straight or branched ones such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, in which the preferred one may be methyl, ethyl or 25 isopropyl.

Suitable "optionally substituted lower alkyl" may include lower alkyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, aryloxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "lower alkoxy" may include straight or branched ones such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy or the like.

Suitable "optionally substituted lower alkoxy" may include lower alkoxy which is optionally substituted by suitable substituent(s) such as hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "cyclo(lower)alkyl" may be cyclo(C3-C8)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclohexyl.

Suitable "lower alkenyl" may include straight or branched ones such as vinyl, propenyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl or the like, in which the preferred one may be vinyl.

Suitable "optionally substituted lower alkenyl" may include lower alkenyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "lower alkynyl" may include straight or branched ones such as ethynyl, propynyl, butynyl, pentynyl, hexynyl or the like, in which the preferred one may be ethynyl.

5        Suitable "optionally substituted lower alkynyl" may include lower alkynyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

10      Suitable "aryl" and "aryl" moiety in the term of "aryloxy" or "arylthio" may include phenyl, naphthyl, indenyl, anthryl, or the like, in which the preferred one may be (C6-C10) aryl, and the more preferred one may be phenyl.

15      Suitable "aryl(lower)alkyl" may include phenyl(lower)alkyl (e.g. benzyl, phenethyl, etc.), diphenyl(lower)alkyl (e.g. benzhydryl, etc.), triphenyl(lower)alkyl (e.g. trityl, etc.), naphthyl(lower)alkyl, indenyl(lower)alkyl or

20      anthryl(lower)alkyl and the like, in which the preferred one may be phenyl(lower)alkyl, and the more preferred one may be phenyl(C1-C4)alkyl.

Suitable "optionally substituted aryl" may include aryl which is optionally substituted by suitable

25      substituent(s), preferably 1 to 3 substituent(s), such as

lower alkyl, lower alkoxy, hydroxy, halogen, etc. Suitable examples of optionally substituted aryl include lower alkylphenyl, lower alkoxyphenyl and halophenyl.

Suitable "heterocyclic group" may be saturated or 5 unsaturated monocyclic or polycyclic heterocyclic groups containing at least one heteroatom selected from among oxygen, sulfur and nitrogen.

The particularly preferred example of said heterocyclic group may include

10 3- through 8-membered unsaturated heteromonocyclic groups containing 1 through 4 nitrogen atom(s), such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 15 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g. 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic 20 groups containing 1 through 4 nitrogen atom(s), such as azetidinyl, pyrrolidinyl, imidazolidinyl, piperidyl (e.g. piperidino, etc.), piperazinyl, etc.;

unsaturated condensed heterocyclic groups containing 1 through 5 nitrogen atom(s), such as indolyl, 25 isoindolyl, indolizinyl, benzimidazolyl, quinolyl,

isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g. tetrazolo[1,5-b]pyridazinyl etc.), dihydrotriazolopyridazinyl, etc.;

3- through 8-membered unsaturated heteromonocyclic 5 groups containing 1 or 2 oxygen atoms and 1 through 3 nitrogen atom(s), such as oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic 10 groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atoms, such as morpholinyl, oxazolidinyl (e.g. 1,3-oxazolidinyl etc.), etc.;

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen 15 atom(s), such as benzoxazolyl, benzoxadiazolyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl, 20 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolidinyl etc.;

25 3- through 8-membered unsaturated heteromonocyclic

groups containing 1 sulfur atom, such as thiaryl etc.;

unsaturated condensed heterocyclic groups

containing 1 or 2 sulfur atoms and 1 through 3 nitrogen atom(s), such as benzothiazolyl, benzothiadiazolyl, etc.;

5 3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as furyl, pyranyl, dioxolyl, etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as oxolanyl,

10 tetrahydropyranyl (e.g. tetrahydro-2H-pyran-2-yl etc.), dioxolanyl, etc.; and

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s), such as isobenzofuranyl, chromenyl (e.g. 2H-chromen-3-yl etc.), dihydrochromenyl 15 (e.g. 3,4-dihydro-2H-chromen-4-yl etc.), etc.

Suitable "optionally substituted heterocyclic group" may include heterocyclic group which is optionally substituted by suitable substituent(s), preferably 1 to 3 substituent(s), such as lower alkyl, lower alkoxy, hydroxy, 20 halogen, or the like.

Suitable "N-containing heterocyclic group" may be aforesaid "heterocyclic group", in which said group contains at least one N atom in its ring members, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl, 25 tetrazolyl, dihydrotriazinyl, azetidinyl, pyrrolidinyl,

imidazolidinyl, piperidyl, piperazinyl, indolyl,  
isoindolyl, indazolyl, benzotriazolyl,  
dihydrotriazolopyridazinyl, morpholinyl, oxazolidinyl,  
thiazolynyl, thiazolidinyl, etc.

5        Suitable "heteroaryl" and "heteroaryl" moiety in the term of "heteroaryl(lower)alkyl" may be aforesaid "heterocyclic group", in which those categorized as an aromatic heterocyclic group, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl,  
10      pyridazinyl, triazolyl, tetrazolyl, dihydrotriazinyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl, dihydrotriazolopyridazinyl, oxazolyl, isoxazolyl,  
15      oxadiazolyl, benzoxazolyl, benzoxadiazolyl, thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl, thienyl, benzothiazolyl, benzothiadiazolyl, furyl, pyranyl, dioxolyl, isobenzofuranyl, chromenyl, dihydrochromenyl, etc.  
20      Suitable "acyl" may include lower alkanoyl, aroyl, carboxy, protected carboxy, and the like.

         Suitable examples of aforesaid "lower alkanoyl" may be formyl, acetyl, propionyl, butyryl, isobutyryl, pivaloyl, hexanoyl, or the like, in which the preferred one  
25      may be (C1-C4) alkanoyl.

Suitable examples of aforesaid "aroyl" may be benzoyl, toluoyl, or the like.

Suitable examples of aforesaid "protected carboxy" may be

- 5        i) esterified carboxy, in which suitable esterified carboxy may include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.), aryl(lower)alkoxycarbonyl (e.g. 10 benzyloxycarbonyl, phenethyloxycarbonyl, 2-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 4-phenylpentyloxycarbonyl, 1,3-diphenylhexyloxycarbonyl, etc.), and the like;
- 15        ii) amidated carboxy, in which suitable amidated carboxy may include carbamoyl, N-(lower)alkylcarbamoyl (e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N-pentylcarbamoyl, N-hexylcarbamoyl, etc.), N,N-di(lower)alkylcarbamoyl [e.g. N,N-dimethylcarbamoyl, 20 N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-di(t-butyl)carbamoyl, N-pentyl-N-hexylcarbamoyl, etc.], N-lower alkyl-N-aryl(lower)alkylcarbamoyl (e.g. N-methyl-N-benzylcarbamoyl, etc), and the like.
- 25        Suitable "halogen" may be fluoro, chloro, bromo and

iodo.

Suitable "a leaving group" may include halogen, hydroxy, acyloxy such as alkanoyloxy (e.g. acetoxy, propionyloxy, etc.) or sulfonyloxy (e.g. mesyloxy, 5 tosyloxy, etc.), or the like.

Suitable "optionally substituted amino" may include amino, mono- or di-(lower)alkylamino (e.g. methylamino, dimethylamino, methylethylamino, etc.), acylamino (e.g. lower alkoxy carbonylamino (e.g. methoxycarbonylamino, 10 ethoxycarbonylamino, etc.), sulfonylamino (e.g. mesylamino, etc.), ureido, etc.), or the like.

The processes for preparing the object pyrazine compound (I) are explained in detail in the following.

15

#### Process 1

The compound (I) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to coupling reaction with the compound (III) or a salt thereof.

20 This reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, methanol, ethanol, 25 diethyl ether, 1,3-dimethyl-2-imidazolidinone,

N-methylpyrrolidone, N,N'-dimethylpropyleneurea, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

Some of the present reaction is preferably carried out in the presence of an organic or inorganic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydride or hydroxide or alkoxide or carbonate or hydrogencarbonate or alcanoic acid thereof, trialkylamine (e.g. triethylamine, trimethylamine, etc.), hydrazine, pyridine compound (e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), quinoline, and the like.

Some of the present reaction is preferably carried out in the presence of a catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine) palladium(0), and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

20 Process 2

The compound (Iba) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to hydrolysis.

This reaction is carried out in accordance with a conventional method.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine (e.g. triethylamine, trimethylamine, etc.), hydrazine, pyridine compound (e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), 1,5-diazabicyclo[4.3.0]non-5-ene, quinoline, 10 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, 15 trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).

The elimination using Lewis acid such as boron tribromide, boron trichloride, boron trifluoride, aluminum chloride or the like is preferably carried out in the 20 presence of cation trapping agents (e.g. anisole, phenol, etc.).

The hydrolysis in this case usually carried out in the presence of an acid including Lewis acid, and these 25 acid(s) including Lewis acid(s) can be used in the mixture,

and the point(s) or the number of being hydrolyzed can be different by the condition (see the example part (examples 2, 7, 10 and 15) in detail).

The reaction is usually carried out in a solvent such 5 as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the 10 reaction, or a mixture thereof.

A liquid base or acid can be also used as the solvent.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

### Process 3

15 The compound (Ic) or a salt thereof can be prepared by subjecting the compound (Ib) or a salt thereof to the alkylation with the compound (IV) or a salt thereof.

Suitable salt of the compound (IV) can be referred ones as exemplified for the compound (I).

20 This reaction is carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, dichloromethane, 1,2-dichloroethane, formamide, N,N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl ether, dioxane, 25 1,2-dimethoxyethane, tetrahydrofuran, dimethyl sulfoxide,

or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities. Among the solvents, hydrophilic solvents may be used in a mixture with water. When the compound (IV) is in a liquid 5 state, it can also be used as a solvent. The reaction is preferably conducted in the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal alkoxide (e.g. potassium t-butoxide), alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride 10 (e.g. sodium hydride, etc.), or organic base such as trialkylamine (e.g. triethylamine, etc.), or basic resin, and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, 15 under warming or heating.

The present reaction is preferably carried out in the presence of alkali metal halide (e.g. sodium iodide, potassium iodide, etc.), or the like.

When Y is -OH, activation of OH with 20 triphenylphosphine, or the like, and di (lower) alkyl azodicarboxylate (e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc.), or the like, may be necessary.

#### Process 4

25 The compound (Ie) or a salt thereof can be prepared

by subjecting the compound (Id) or a salt thereof to hydrolysis using a base or an acid.

This reaction can be carried out in the same manner as the aforementioned hydrolysis using a base in Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

#### Process 5

The compound (If) or a salt thereof can be prepared by decarboxylation of the compound (Ie) or a salt thereof.

This reaction is carried out in accordance with a conventional method such as thermal decomposition, acid decomposition and the like; more suitable one in this case is thermal decomposition.

The reaction is usually carried out in a conventional inactive solvent such as quinoline, dichlorobenzene, mesitylene, dodecane, Dowtherm® (phenyl ether-biphenyl eutectic mixture) or any other organic solvent which does not adversely affect the reaction, or a mixture thereof; more suitable one in this case is 1,2-dichlorobenzene.

The reaction temperature is not critical, and the reaction is usually carried out on 100°C-200°C heating condition.

#### Process 6

The compound (Ig) or a salt thereof can be prepared

by amidation of the compound (Ie) or a salt thereof.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, dichloromethane, 1,2-dichloroethane, 5 tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.

The reaction is preferably carried out in the presence of a conventional condensing agent such as 10 N,N'-dicyclohexylcarbodiimide; N-cyclohexyl- N'-morpholinoethyl-carbodiimide; N-cyclohexyl- N'-(4-diethylaminocyclohexyl)-carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl- N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonyl- 15 bis-(2-methylimidazole); pentamethyleneketene- N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; 20 triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(*m*-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(*p*-chlorobenzenesulfonyloxy)- 6-chloro-1*H*-benzotriazole; so-called Vilsmeier reagent 25 prepared by the reaction of N,N-dimethylformamide with

thionyl chloride, phosgene, phosphorus oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)-alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

10 Process 7

The compound (Ih) or a salt thereof can be prepared by subjecting the compound (If) or a salt thereof to halogenation with a halogenating agent such as N-halosuccinimide (e.g. N-chlorosuccinimide, 15 N-bromosuccinimide, etc.), or the like.

The reaction is usually carried out in a solvent such as tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which 20 does not adversely affect the reaction, or a mixture thereof.

Process 8

The compound (Ij) or a salt thereof can be prepared by subjecting the compound (Ih) or a salt thereof to 25 coupling reaction with the compound (V) or a salt thereof.

This reaction can be carried out in the same manner as the aforementioned coupling reaction in Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can

5 be referred to those of Process 1.

Process A

The compound (VII) or a salt thereof can be prepared by subjecting the compound (VI) or a salt thereof to hydrolysis using an acid (exemplified by Step 1). This 10 reaction can be carried out in the same manner as the aforementioned hydrolysis using an acid in Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

15 And the object compound (VIII) can be prepared by subjecting the compound (VII) or a salt thereof to the alkylation with the compound (IV) or a salt thereof (exemplified by Step 2). This reaction can be carried out in the same manner as in the aforementioned Process 3, and 20 therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 3.

Process B

The compound (X) or a salt thereof can be prepared 25 from the acetylation of the compound (IX) (exemplified by

Step 1) by the methods disclosed in Preparation 1 mentioned later or the similar manner thereto.

And the object compound (XI) can be prepared by subjecting the compound (X) to the oxime-formation reaction 5 (exemplified by Step 2) that disclosed in Preparation 2 mentioned later or the similar manners thereto.

#### Process C

The compound (XII) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with 10 aminomalonitrile or a salt thereof.

The present reaction is preferably carried out in the presence of a catalyst such as *p*-toluenesulfonic acid, and the like.

This reaction is usually carried out in a 15 conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, *N,N*-dimethylformamide, methanol, ethanol, isopropanol, *t*-butanol, diethyl ether, isopropyl ether, a 20 mixture thereof or any other organic solvent which does not adversely affect the reaction.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

25 This reaction can be carried out by the method

disclosed in Preparation 3 mentioned later or the similar manner thereto.

Process D

The compound (XVI) or a salt thereof can be prepared 5 by subjecting the compound (XIII) or a salt thereof to hydrolysis using an acid.

Process E

The compound (II) or a salt thereof can be prepared by reacting the compound (XV) or a salt thereof with the 10 compound (XVI) or a salt thereof.

This reaction is usually carried out in a conventional solvent such as acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 15 ethyl acetate, N,N-dimethylformamide, diethyl ether, isopropyl ether, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

This reaction can be carried out by the method disclosed in Preparation 4 mentioned later or the similar 20 manner thereto.

Above processes, all starting materials and product compounds may be salts. The compounds of above processes can be converted to salts according to a conventional 25 method.

The object compound (I) of the present invention is an adenosine antagonist and possesses the various pharmacological actions as stated before.

5 In order to show the usefulness of the compound (I) of the present invention, the pharmacological test result of the representative compound of the present invention is shown in the following.

10 Test 1 : Adenosine antagonistic activity

[I] Test method

The adenosine antagonistic activity [Ki(nM)] of the test compound was examined by radioligand binding techniques using 8-cyclopentyl-1,3-dipropylxanthine,

15 [dipropyl-2,3-<sup>3</sup>H(N)] ([<sup>3</sup>H]DPCPX, 4.5nM) for human A<sub>1</sub> receptor and [<sup>3</sup>H]CGS 21680 (20nM) for human A<sub>2a</sub> receptor.

[II] Test compound

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-phenyl-2-pyrazinecarboxamide (Example 4)

20 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-phenyl-2-pyrazinecarbonitrile (Example 11)

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-  
6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile  
(Example 39)

25 3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-

1, 6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

(Example 46)

5-[5-amino-6-(hydroxymethyl)-3-phenyl-  
2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (Example 47)

5 3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-  
1, 6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

(Example 49)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-  
1-isopropyl-2(1H)-pyridone (Example 53)

10 5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-  
2(1H)-pyridone (Example 115)

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-  
isopropyl-2(1H)-pyridone (Example 129)

15 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-  
isopropyl-2(1H)-pyridone (Example 141)

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-  
isopropyl-2(1H)-pyridone (Example 144)

5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-  
isopropyl-2(1H)-pyridone (Example 151)

## [III] Test result

Table 1

Test compound		Adenosine receptor binding (Ki:nM)	
	(Example No.)	A <sub>1</sub>	A <sub>2a</sub>
	4	5.09	2.34
5	11	22.47	2.35
	39	23.99	6.52
	46	5.25	1.49
	47	22.27	7.52
	49	6.07	1.69
10	53	0.93	0.91
	115	4.89	0.84
	129	10.71	3.90
	141	0.61	0.23
	144	1.78	0.54
15	151	1.57	0.32

Test 2 : Anticatalepsy activity in Mouse

## [I] Test method

The test compound (3.2mg/kg) was administered orally  
 20 with ddY mice(n=7). Then, haloperidol (0.32mg/kg) was  
 injected intraperitoneally 30 min. after the

administration of the compound. Thirty min. after the injection, the cataleptic responses of mice were measured. The forelimbs of each mouse were placed on a 3 cm high, 3 mm wide horizontal bar, and the duration of cataleptic posture was measured for up to 30 sec.

[II] Test compound

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 4)

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-

10 5-phenyl-2-pyrazinecarbonitrile (Example 11)

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile  
(Example 39)

3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide  
(Example 46)

5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (Example 47)

3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide  
(Example 49)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-1-isopropyl-2(1H)-pyridone (Example 53)

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (Example 115)

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-

isopropyl-2(1H)-pyridone (Example 129)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-

isopropyl-2(1H)-pyridone (Example 141)

5 5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-

isopropyl-2(1H)-pyridone (Example 144)

5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-

isopropyl-2(1H)-pyridone (Example 151)

10

15

20

25

## [III] Test result

Table 2

Test compound (Example No.)	Manifestation rate of Catalepsy	
		(number of mouse)
4		0/7
11		0/7
5 39		0/7
46		0/7
47		1/7
49		1/7
53		0/7
10 115		0/7
129		0/7
141		0/7
144		0/7
151		0/7

15

The pyrazine compound (I) and a salt thereof of this invention are useful as adenosine antagonists (especially, A<sub>1</sub> receptor and A<sub>2</sub> (particularly A<sub>2a</sub>) receptor dual antagonists) and for the prevention and/or the treatment 20 of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying

Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, 5 hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, 10 ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic 15 attack, angina pectoris, and the like.

Adenosine antagonists can be useful for Parkinson's disease by co-administrating with L-3,4-dihydroxy-phenylalanine (L-DOPA), which is the most popular drug for Parkinson's disease (R. Grondin et al., 20 *Neurology*, 52, 1673 (1999)). So the combination use of the pyrazine compound (I) and a salt thereof of this invention with L-DOPA may be also useful for treatment and/or prevention of Parkinson's disease with decreasing or reducing the side effect such as the onset of dyskinesia 25 eliciting by the long-team application of L-DOPA, and so

on.

Further, in view of the field using these compounds for as a medicament, these compounds should be durable to some degree. And the duration time of the pyrazine compound 5 (I) or a salt thereof of this invention are expected to be long-lasting.

The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which 10 contains the pyrazine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral 15 (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, 20 aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. In addition, auxiliary, stabilizing agents, thickening agents, coloring agents and perfumes may be used where necessary. The pyrazine compound (I) or a pharmaceutically acceptable 25 salt thereof is included in a pharmaceutical composition

in an amount sufficient to produce the desired aforesaid pharmaceutical effect upon the process or condition of diseases.

For applying the composition to a human being or an animal, it is preferable to apply it by intravenous, intramuscular, pulmonary or oral administration, or insufflation. While the dosage of therapeutically effective amount of the pyrazine compound (I) varies depending on the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.1 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal, and in case of oral administration, a daily dose of 0.5 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal is generally given for the prevention and/or treatment of the aforesaid diseases.

The following preparations and examples are given for the purpose of illustrating the present invention in more detail.

5 The abbreviations, symbols and terms used in the preparations and examples have the following meanings.

	AcOH	acetic acid
	CHCl <sub>3</sub>	chloroform
	CH <sub>2</sub> Cl <sub>2</sub>	dichloromethane
10	DME	1,2-dimethoxyethane
	DMF	N,N-dimethylformamide
	DMSO	dimethyl sulfoxide
	EtOAc	ethyl acetate
	EtOH	ethanol
15	IPA	isopropyl alcohol
	IPE	isopropyl ether
	MeOH	methanol
	MeCN	acetonitrile
	NMP	N-methylpyrrolidone
20	THF	tetrahydrofuran
	HCl	hydrochloric acid
	NET <sub>3</sub>	triethylamine
	t-BuOK	potassium tert-butoxide
	K <sub>2</sub> CO <sub>3</sub>	potassium carbonate
25	MgSO <sub>4</sub>	magnesium sulfate

	NaOAc	sodium acetate
	Na <sub>2</sub> CO <sub>3</sub>	sodium carbonate
	NaH	sodium hydride
	NaHCO <sub>3</sub>	sodium bicarbonate
5	NaOH	sodium hydroxide
	EtI	ethyl iodide
	MeI	methyl iodide
	<i>n</i> -PrBr	<i>n</i> -propyl bromide
	<i>i</i> -PrI	isopropyl iodide
10	CuI	cuprous iodide (copper(I) iodide)
	PdCl <sub>2</sub> (PPh <sub>3</sub> ) <sub>2</sub>	dichlorobis(triphenylphosphine)-
		palladium(II)
	Pd(OAc) <sub>2</sub>	palladium(II) acetate
	Pd(PPh <sub>3</sub> ) <sub>4</sub>	tetrakis(triphenylphosphine)-
15		palladium(II)
	aq.	aqueous
	conc.	concentrated
	sat.	saturated

20 Preparation 1

2-Methoxybromopyridine (25 g) and *n*-butyl vinyl ether (66.6 g) were dissolved in DMF (250 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (3.62 g) and Pd(OAc)<sub>2</sub> (896 mg) and aq. K<sub>2</sub>CO<sub>3</sub> under nitrogen atmosphere. The reaction mixture was stirred for 2 hours

at 100-120°C. The mixture was cooled to 25°C. To the solution was added 1N aq. HCl (625 ml). The solution was stirred for 1 hour at 25-30°C. The solution was portioned to EtOAc and water. The organic layer was separated. The aqueous layer 5 was extracted with EtOAc. The combined organic solution was washed with water and brine, and dried over MgSO<sub>4</sub>. Evaporation of solvent in vacuo gave oily residue. The residue was purified by chromatography on silica gel (EtOAc : n-Hexane=1 : 5, v/v) to give.

10 2-methoxy-5-acetylpyridine as a solid (12.14 g).  
<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 2.56 (3H, s), 3.95 (3H, s), 6.92 (1H, d, J=8.4 Hz), 8.17 (1H, dd, J=2.4, 8.4 Hz), 8.30 (1H, d, J=2.4 Hz)  
MS(ESI<sup>+</sup>) : 152[M+H]<sup>+</sup>

15 Preparation 2

2-Methoxy-5-acetylpyridine (12.1 g) and t-butyl nitrite (9.92 g) were dissolved in THF (120 ml). The solution was cooled at 0-5°C. To the solution was added t-BuOK (10.8 g) at 5-25°C. The reaction mixture was stirred 20 at 25°C for 2 hours. To the mixture was added 1N HCl (105 ml). The solution was portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with 10% aq. NaOAc and brine successively, dried over 25 MgSO<sub>4</sub>. Evaporation of solvent in vacuo gave solid residue.

The residue was pulverized with IPE (150 ml). The precipitated crystals were collected by filtration, to give (1E)-(6-methoxy-3-pyridyl)(oxo)acetaldehyde oxime as a solid (5.45 g) (anti, syn mixture (anti : syn=1:1)).

5 Evaporation of solvent in the filtrate gave a residue. The residue was pulverized with IPE. The precipitated crystals were collected by filtration, to give (1E)-(6-methoxy-3-pyridyl)(oxo)acetaldehyde oxime as a solid (2.5 g) (anti, syn mixture (anti : syn=1:1)).

10 anti form

$^1\text{H-NMR}(\text{DMSO-d}_6 \delta)$  : 3.95 (3H, s), 6.95 (1H, d,  $J=8.4$  Hz), 8.00 (1H, s), 8.23 (1H, dd,  $J=2.4, 8.4$  Hz), 8.85 (1H, d,  $J=2.4$  Hz), 12.7 (1H, s)

MS (ESI $^+$ ) : 181[M+H] $^+$ , 203[M+Na] $^+$

15 syn form

$^1\text{H-NMR}(\text{DMSO-d}_6 \delta)$  : 3.96 (3H, s), 7.00 (1H, d,  $J=8.4$  Hz), 7.59 (1H, s), 8.09 (1H, dd,  $J=2.4, 8.4$  Hz), 8.64 (1H, d,  $J=2.4$  Hz), 11.8 (1H, s),

MS (ESI $^+$ ) : 181[M+H] $^+$ , 203[M+Na] $^+$

20 Preparation 3

(1E)-(6-Methoxy-3-pyridyl)(oxo)acetaldehyde oxime (5.4 g) and aminomalonitrile *p*-toluenesulfonate (7.6 g) were suspended in 2-propanol (108 ml) and stirred at 25°C. To the mixture was added *p*-toluenesulfonic acid (5.71 g).

25 The mixture was heated at 50°C for 2 hours, then at ambient

temperature for 1 hour. The above reaction mixture was concentrated in vacuo. To the concentrated solution was added sat. aq. NaOAc. Crystals were precipitated. The suspension was stirred at 20°C for 15 hours. The crystals 5 were collected by filtration, and dried in vacuo to give 3-amino-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide as powder (6.65 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.90 (3H, s), 6.92 (1H, d, J=8.6 Hz), 8.06 (2H, brs), 8.23 (1H, dd, J=2.4, 8.6 Hz), 8.74 (1H, d, 10 J=2.4 Hz), 9.21 (1H, s)

MS(ESI<sup>+</sup>) : 244[M+H]<sup>+</sup>,

IR(KBr) : 3386, 3186, 2238, 1639, 1610, 1489, 1189 cm<sup>-1</sup>

Preparation 4

3-Amino-6-(6-methoxy-3-pyridyl)-  
15 2-pyrazinecarbonitrile 4-oxide (6.65 g) was dissolved in DMF (133 ml). To the solution was added phosphorus oxychloride (12.6 g) at 25°C. The mixture was stirred at ambient temperature for 2 hours. To the mixture was added water (520 ml). The solution was stirred at 20-25°C for 15 20 hours. The precipitated crystals were collected by filtration and dried in vacuo, to give 3-amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile as powder (4.6 g). The filtrate was extracted with EtOAc. The organic solution was washed with brine, dried over MgSO<sub>4</sub>.  
25 Evaporation of solvent in vacuo gave oily residue. The

residue was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 1, v/v) to give 3-amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile as powder (1.0 g).

5  $^1\text{H-NMR}$  (DMSO- $d_6$   $\delta$ ) : 3.93 (3H, s), 6.92 (1H, d,  $J=8.6$  Hz), 7.88 (2H, s), 7.95 (1H, dd,  $J=2.4, 8.6$  Hz), 8.43 (1H, d,  $J=2.4$  Hz)

MS (ESI $^+$ ) : 262 [M+H] $^+$ , 284 [M+Na] $^+$

IR (KBr) : 3384, 3187, 2227, 1656, 1610, 1475, 1209  $\text{cm}^{-1}$

10 Preparation 5

2-Methoxy-5-bromo-pyridine (615 g) was dissolved in 6N HCl (3 l). The solution was heated at 99–105°C. The mixture was refluxed and stirred for 5 hours. The above reaction mixture was cooled to 5°C. The pH of the solution 15 was adjusted to 6.5 with 10% aq. NaOH. The precipitated crystal was collected by filtration and washed with water (500 ml), and dried in vacuo, to give 5-bromo-2(1H)-pyridone (570 g) as crystal.

18  $^1\text{H-NMR}$  (DMSO- $d_6$   $\delta$ ) : 6.36 (1H, d,  $J=9.8$  Hz), 7.55 (1H, dd,  $J=2.8, 9.8$  Hz), 7.69 (1H, d,  $J=2.4$  Hz), 11.7 (1H, s)

MS (ESI $^+$ ) : 196 and 198 [M+Na] $^+$

Preparation 6

21  $t\text{-BuOK}$  (32.2 g) was added to the suspension of 5-bromo-2(1H)-pyridone (50 g) in DME (500 ml). The mixture 25 was stirred for 30 minutes. To the mixture was added  $\text{K}_2\text{CO}_3$

(27.8 g) and 2-iodopropane (81.6 g). The reaction mixture was refluxed with stirring for 3 hours. The above mixture was cooled to 20-25°C. The precipitated salt was removed by filtration and washed with DME (100 ml). Evaporation of 5 solvent in vacuo gave solidly residue. The residue was dissolved in  $\text{CHCl}_3$  (150 ml). The solution was washed with 0.1N HCl and brine, and dried over  $\text{MgSO}_4$ . Evaporation of solvent in vacuo gave solidly residue. To the residue was added *n*-hexane (150 ml) to pulverize the residue. The 10 precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-isopropyl-2(1H)- pyridone (41.2 g).

$^1\text{H-NMR}(\text{DMSO-d}_6 \delta)$  : 1.29 (6H, d,  $J=6.8$  Hz), 4.99 (1H, m), 6.36 (1H, d,  $J=9.6$  Hz), 7.48 (1H, dd,  $J=2.4, 9.6$  Hz), 7.96 (1H, d,  $J=2.4$  Hz)

15 MS (ESI $^+$ ) : 216 and 218[M+H] $^+$ , 238 and 240[M+Na] $^+$

#### Preparation 7

5-Bromo-1-isopropyl-2(1H)-pyridone (50 g) was dissolved in *n*-butyl vinyl ether (250 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (6.3 g) and 20 powdered  $\text{K}_2\text{CO}_3$  (38.2 g) and  $\text{Pd}(\text{OAc})_2$  (1.56 g) at 25°C. The mixture was heated at 90-95°C with stirring for 8 hours. The reaction mixture was cooled to 25-30°C. To the cooled mixture was added  $\text{CHCl}_3$  (125 ml). The precipitated salt was removed by filtration and washed with  $\text{CHCl}_3$  (125 ml). 25 Evaporation of solvent in the filtrate in vacuo gave oily

residue. The residue was dissolved in  $\text{CHCl}_3$  (125 ml). To the solution was added 1N  $\text{HCl}$  (125 ml). The reaction mixture was stirred at 25-30°C for 1 hour. The organic layer was separated. The aqueous layer was extracted with  $\text{CHCl}_3$  (100 ml). The combined organic layer was washed with 10% aq.  $\text{NaHCO}_3$  (50 ml) and dried over  $\text{MgSO}_4$  (25 g) and silica gel (25 g).  $\text{MgSO}_4$  and silica gel were removed by filtration and washed with  $\text{CHCl}_3$ . Evaporation of solvent in the filtrate in vacuo gave oily residue, which was crystallized from 10  $n$ -hexane (500 ml). The crystal was collected by filtration and dried in vacuo at 40°C, to give

5-acetyl-1-isopropyl-2(1H)-pyridone (32.35 g).

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$   $\delta$ ) : 1.37 (6H, d,  $J=6.8$  Hz), 2.47 (3H, s), 5.02 (1H, m), 6.44 (1H, d,  $J=9.6$  Hz), 7.82 (1H, dd,  $J=2.6$ , 15 9.6 Hz), 8.41 (1H, d,  $J=2.6$  Hz)

MS (ESI $^+$ ) : 180 [M+H] $^+$ , 202 [M+Na] $^+$

#### Preparation 8

5-Acetyl-1-isopropyl-2(1H)-pyridone was dissolved in  $\text{CH}_2\text{Cl}_2$  (300 ml). The solution was cooled to -30~-25°C. 20 To the cooled solution were added 4N hydrogen chloride in dioxane (55.3 ml) and *t*-butyl nitrite (10.4 g) at -30~-25°C. The temperature of the reaction mixture was raised to 20-25°C. The mixture was stirred at the same temperature for 3 hours. The precipitated crystal was collected by 25 filtration, and dried in the air at ambient temperature,

to give (1*E*)-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo)acetaldehyde oxime (14.0 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.35 (6H, d, J=6.8 Hz), 5.02 (1H, m), 6.47 (1H, d, J=9.6 Hz), 7.89 (1H, dd, J=2.4, 9.6 Hz), 8.00

5 (1H, s), 8.69 (1H, d, J=2.4 Hz), 12.65 (1H, brs)

MS(ESI<sup>+</sup>) : 209[M+H]<sup>+</sup>, 231[M+Na]<sup>+</sup>

IR(KBr) : 3129, 1660, 1617, 1529, 1018 cm<sup>-1</sup>

#### Preparation 9

The mixture of (1*E*)-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo)acetaldehyde oxime (14 g) and aminomalonitrile *p*-toluenesulfonate (17 g) and IPA (210 ml) was heated at 75-80°C and stirred for 2 hours at the same temperature. The reaction mixture was cooled to 0-5°C and stirred for 2 hours. The precipitate was collected by filtration, and dried in vacuo, to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (9.2 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.36 (6H, d, J=6.8 Hz), 5.09 (1H, m), 6.48 (1H, d, J=9.6 Hz), 7.92-7.99 (3H, m), 8.28 (1H, d, J=2.6 Hz), 9.25 (1H, s)

MS(ESI<sup>+</sup>) : 293[M+Na]<sup>+</sup>

IR(KBr) : 3122, 2200, 1656, 1598, 1531, 1174 cm<sup>-1</sup>

#### Preparation 10

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (9 g) was

dissolved in 25% hydrogen bromide solution of AcOH (90 ml) at 20-25°C. The reaction mixture was stirred for 2 hours at ambient temperature. To the reaction mixture was added dioxane (180 ml). The suspension was stirred for 2 hours 5 at ambient temperature. The precipitate was collected by filtration and washed with dioxane, and dried in the air at ambient temperature. The above powder was suspended in water (90 ml). The pH of the suspension was adjusted to 8-8.5 with 1N NaOH (70 ml). The suspension was stirred at ambient 10 temperature. The precipitate was collected by filtration and washed with water, and dried in vacuo at 50°C, to give 3-amino- 6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (8.80 g).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.39 (6H, d, J=6.8 Hz), 5.10 (1H, m), 15 6.46 (1H, d, J=9.4 Hz), 7.88 (2H, s), 7.89 (1H, s), 8.32 (1H, dd, J=2.4, 9.4 Hz), 8.41 (1H, d, J=2.4 Hz), 8.51 (1H, s), 9.15 (1H, s)

MS(ESI<sup>+</sup>) : 312 [M+Na]<sup>+</sup>

IR(KBr) : 3440, 1660, 1596, 1554, 1186 cm<sup>-1</sup>

20 Preparation 11

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (8 g) was dissolved in DMF (80 ml). The solution was cooled to -30°C. To the cooled solution was added phosphoryl chloride (12.7 25 g) dropwise at -30~-40°C. After addition of phosphoryl

chloride, the temperature of the reaction mixture was raised to -10~-5°C. The mixture was stirred at -10~-5°C for 1 hour. To the reaction mixture was added water (400 ml). The suspension was stirred at 30-35°C for 15 hours. The pH 5 of the suspension was adjusted to 4.5. The suspension was cooled to 0-5°C and stirred at the same temperature for 2 hours. The precipitate was collected by filtration and washed with water, and dried in vacuo at 40-50°C, to give 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-10 3-pyridyl)-2-pyrazinecarboxamide (7.1 g).

$^1\text{H-NMR}$  (DMSO- $\text{d}_6$   $\delta$ ) : 1.34 (6H, d,  $J=7.0$  Hz), 5.09 (1H, m), 6.44 (1H, d,  $J=9.4$  Hz), 7.74 (1H, s), 7.85 (1H, dd,  $J=2.4$ , 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d,  $J=2.4$  Hz), 8.13 (1H, s)

15  $\text{MS}(\text{ESI}^+)$  : 330 and 332[M+Na] $^+$

IR(KBr) : 3284, 1673, 1604, 1461, 1187  $\text{cm}^{-1}$

#### Preparation 12

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-10 3-pyridyl)-2-pyrazinecarboxamide 4-oxide (29.1 g) was dissolved in DMF (290 ml). The solution was cooled to -30°C. To the cooled solution was added phosphoryl chloride (46.3 g) dropwise at -30~-40°C. After addition of phosphoryl chloride, the temperature of the reaction mixture was raised to 40-45°C. The mixture was stirred at 40-45°C for 25 1 hour. To the reaction mixture was added water (1160 ml).

The suspension was stirred at 30-35°C for 15 hours. The pH of the suspension was adjusted to 7 with 12% aq. NaOH (400 ml). The suspension was cooled to 0-5°C and stirred at the same temperature for 2 hours. The precipitate was collected 5 by filtration and washed with water, and dried in vacuo at 40-50°C, to give 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (17.2 g).  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.34 (6H, d, J=7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J=9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J=2.4, 10 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J=2.4 Hz), 8.13 (1H, s)

MS (ESI<sup>+</sup>) : 330 [M+Na]<sup>+</sup>

IR (KBr) : 3291, 1662, 1600, 1465, 1182 cm<sup>-1</sup>

Preparation 13

15 To a solution of 1-(diphenylmethyl)-3-azetidinol hydrochloride (5.0 g) in DMF (25 ml), was added sodium hydride under ice-bath cooling. After 10 minute stirring at the same temperature, the mixture was allowed to warm to 25°C and then stirred for 15 hours. EtOAc (500 ml) and 20 water (200 ml) were poured into the mixture. The organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel; 200 ml, toluene : EtOAc=15 : 1 - 8 : 1) to give 25 1-(diphenylmethyl)-3-methoxyazetidine (3.41 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 2.7-2.9 (2H, m), 3.12 (3H, s), 3.3-3.5 (2H, m), 3.99 (1H, m), 4.40 (1H, s), 7.1-7.4 (6H, m), 7.3-7.5 (4H, m)

MS(ESI<sup>+</sup>) : 254[M+H]<sup>+</sup>

5 Preparation 14

To a solution of 1-(diphenylmethyl)-3-methoxyazetidine (3.4 g) in MeOH (35 ml), was added 20% palladium hydroxide on carbon (0.7 g). And then the mixture was stirred under hydrogen atmosphere for 2.5 hours. 1N HCl (20 ml) was added to the mixture and the catalyst was removed by filtration and washed with 1N HCl. The solvent was removed under reduced pressure. Water and EtOAc were poured into the residue, and the aqueous layer was separated, washed with EtOAc. The solvent was removed under reduced pressure and the residue was azeotroped with EtOH and dried in vacuo. n-Hexane was poured into the residue and a crystal was isolated by filtration, washed with n-hexane, and dried in vacuo to give 3-methoxyazetidine hydrochloride (1.58 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.21 (3H, s), 3.6-3.9 (2H, m), 4.0-4.4 (3H, m)

MS(ESI<sup>+</sup>) : 88[M+H]<sup>+</sup> (free form)

Preparation 15

The mixture of 5-bromo-2(1H)-pyridone (200 g) and MeI (324 g) and K<sub>2</sub>CO<sub>3</sub> (318 g) in DME (2 l) was heated at 80°C with stirring for 2 hours. The above mixture was cooled to

room temperature. The precipitated salt was removed by filtration and washed with DME. Evaporation of solvent in the filtrate in vacuo gave oily residue. The residue was portioned to EtOAc and water. The organic layer was 5 separated. Aqueous layer was extracted with EtOAc twice. The combined organic solution was dried over  $MgSO_4$ . Evaporation of solvent in vacuo gave crystal residue. The residue was pulverized with IPE and *n*-hexane (1 : 3, 1000 ml). The precipitate was collected by filtration and dried 10 in vacuo to give 5-bromo-1-methyl-2(1*H*)-pyridone as white powder (182.5 g).

$^1H$ -NMR (DMSO- $d_6$   $\delta$ ) : 3.40 (3H, s), 6.36 (1H, d,  $J=9.6$  Hz), 7.51 (1H, dd,  $J=2.8$ , 9.6 Hz), 8.03 (1H, d,  $J=2.8$  Hz)  
MS (ESI $^+$ ) : 210 and 212[M+Na] $^+$

15 Preparation 16

5-Bromo-1-methyl-2(1*H*)-pyridone (150 g) was dissolved in DMF (1500 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (21.7 g), *n*-butyl vinyl ether (400 g), and 3*M* aq. potassium carbonate (262.5 ml) 20 and  $Pd(OAc)_2$  (10.2 g). The mixture was heated at 80°C and stirred for 3 hours at the same temperature. The reaction mixture was cooled to 25-30°C and poured to 1*N* HCl (1485 ml). The mixture was stirred for 2 hours at 30-40°C. The solution was extracted with EtOAc (1500 ml, three times). 25 The aqueous layer was extracted with  $CH_2Cl_2$  (1000 ml, three

times). The collected organic solution was dried over  $MgSO_4$ . Evaporation of solvent gave solidly residue, which was pulverized with IPA (150 ml) and IPE (1500 ml). The suspension was stood in the refrigerator overnight. The 5 precipitate was collected by filtration, dried in vacuo, to give 5-acetyl-1-methyl-2(1H)-pyridone as white powder (128 g).

$^1H$ -NMR(DMSO- $d_6$   $\delta$ ) : 2.41 (3H, s), 3.52 (3H, s), 6.42 (1H, d,  $J=9.6$  Hz), 7.84 (1H, dd,  $J=2.4, 9.6$  Hz), 8.66 (1H, d, 10  $J=2.4$  Hz)

MS(ESI $^+$ ) : 152[M+H] $^+$ , 174[M+Na] $^+$

Preparation 17

(1E)-(1-Methyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo) acetaldehyde oxime

15 The title compound was obtained in a similar manner to that of Preparation 8.

$^1H$ -NMR(DMSO- $d_6$   $\delta$ ) : 3.57 (3H, s), 6.47 (1H, d,  $J=9.6$  Hz), 7.93 (1H, dd,  $J=2.4, 9.6$  Hz), 8.03 (1H, s), 8.76 (1H, d, 20  $J=2.4$  Hz), 12.62 (1H, s)

MS(ESI $^+$ ) : 203[M+Na] $^+$

Preparation 18

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide

25 The title compound was obtained in a similar manner to that of Preparation 9.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.50 (3H, s), 6.47 (1H, d, J=9.6 Hz),  
7.96 (2H, s), 7.96-8.02 (1H, m), 8.43 (1H, d, J=2.4 Hz),  
9.04 (1H, s)

MS(ESI<sup>+</sup>) : 244 [M+Na]<sup>+</sup>

5 Preparation 19

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (97 g) was added to 25% hydrogen bromide solution of AcOH (700 ml) at 25-30°C. The mixture was stirred for 2 hours at ambient temperature.

10 To the mixture was added 12% aq. NaOH (2100 ml) and water (1000 ml). The mixture was stirred overnight at the refrigerator. The resultant precipitated crystals were collected by filtration, and washed with water, and dried in vacuo, to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-15 3-pyridyl)-2-pyrazinecarboxamide 4-oxide as powder (52 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.52 (3H, s), 6.45 (1H, d, J=9.6 Hz),  
7.82 (2H, s), 7.92 (1H, s), 8.26 (1H, dd, J=2.6, 9.6 Hz),  
8.54 (1H, s), 8.72 (1H, d, J=2.6 Hz), 8.97 (1H, s)

MS(ESI<sup>+</sup>) : 262 [M+H]<sup>+</sup>, 284 [M+Na]<sup>+</sup>

20 Preparation 20

3-Amino-5-chloro-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Preparation 12.

25 <sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.25 (3H, s), 6.45 (1H, d, J=9.4 Hz),

7.70 (1H, dd,  $J=2.6, 9.4$  Hz), 7.83 (2H, s), 8.06 (1H, d,  $J=2.6$  Hz)

MS (ESI $^+$ ) : 262 and 263 [M+H] $^+$ , 284 and 286 [M+Na] $^+$

Preparation 21

5. To a suspension of 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (1.0 g) in DMF was added phosphoric trichloride (1.07 ml) at -40°C for 20 minutes. This reaction mixture was warmed to -10°C and stirred for 1 hour. To this solution was added 10 water (40 ml) and stirred at 40°C for 14 hours. The pH of the resulting suspension was adjusted to 4.5 with 30% The pH of the aqueous mixture was adjusted to 6-7 with 12% aq. NaOH. The precipitate was collected by filtration and washed with water to give 3-amino-5-chloro-6-(1-methyl-15 6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (263 mg) as a yellow powder.

MS (ESI $^+$ ) : 280 [M+H] $^+$

Example 1

3-Amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile (1.35 g) was dissolved in dioxane (135 ml). To the solution were added phenylboronic acid (1.89 g) and  $Pd(PPh_3)_4$  (179 mg) and  $Na_2CO_3$  (2.19 g) in water (27 ml) at 25°C. The reaction mixture was heated at 80°C for 2 hours, then at ambient temperature for 3 hours. The 25 above mixture was portioned to EtOAc and water. The organic

layer was separated and washed with aq.  $\text{Na}_2\text{CO}_3$  and brine, and dried over  $\text{MgSO}_4$ . Evaporation of solvent in vacuo gave oily residue, which was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 1, v/v) to give

5 3-amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile as yellow crystal which was crystallized from EtOAc (1.15 g).

$^1\text{H-NMR}$ (DMSO- $\text{d}_6$   $\delta$ ) : 3.81 (3H, s), 6.73 (1H, d,  $J=8.6$  Hz), 7.35 (5H, s), 7.51 (2H, s), 7.54 (1H, dd,  $J=2.4, 8.6$  Hz),  
10 7.99 (1H, d,  $J=2.4$  Hz)

MS(ESI $^+$ ) : 304[M+H] $^+$ , 326[M+Na] $^+$

IR(KBr) : 3357, 3183, 2238, 1648, 1598, 1544, 1195  $\text{cm}^{-1}$

m.p. : 201-205°C (IPE)

Example 2

15 3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (500 mg) was dissolved in dioxane (10 ml) and conc. HCl (5 ml). The solution was stirred at 80°C for 5 hours. The reaction mixture was cooled to 25-30°C and concentrated in vacuo to give a residue. To the residue 20 was added water and 1N NaOH to adjust the pH of the aqueous mixture to 6-7. The precipitated crystals were collected by filtration dried in vacuo to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (390 mg).

25  $^1\text{H-NMR}$ (DMSO- $\text{d}_6$   $\delta$ ) : 6.16 (1H, d,  $J=9.4$  Hz), 7.26-7.70 (10H,

m), 8.23 (1H, s), 11.66 (1H, s)

MS (ESI<sup>+</sup>) : 330 [M+Na]<sup>+</sup>

MS (ESI<sup>-</sup>) : 306 [M-H]<sup>-</sup>

IR (KBr) : 3309, 1656, 1610, 1544, 1201 cm<sup>-1</sup>

5 m.p. : 215-220°C (H<sub>2</sub>O)

Example 3

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (61.4 mg) was dissolved in DMF (1 ml).

To the solution were added 1M MeI solution in DMF (0.22 ml) 10 and 0.1M t-BuOK solution in DMF (2.2 ml). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated.

The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO<sub>4</sub>.

15 Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=93 : 7, v/v) to give 3-amino-

6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-

2-pyrazinecarboxamide, which was crystallized from EtOAc 20 (20 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.45 (3H, s), 6.12 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.4, 9.4 Hz), 7.41-7.62 (8H, m), 8.14 (1H, d, J=2.4 Hz), 8.29 (1H, s)

MS (ESI<sup>+</sup>) : 344 [M+Na]<sup>+</sup>

25 IR (KBr) : 3353, 1664, 1599, 1531, 1438 cm<sup>-1</sup>

m.p. : >250°C (EtOAc)

Example 4

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-phenyl-2-pyrazinecarboxamide

5 The title compound was obtained in a similar manner  
to that of Example 3.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.12 (3H, t, J=7.0 Hz), 3.84 (2H, q,  
J=7.0 Hz), 6.18 (1H, d, J=9.4 Hz), 7.21 (1H, dd, J=2.4, 9.4  
Hz), 7.40-7.72 (8H, m), 7.89 (1H, d, J=2.4 Hz), 8.27 (1H,  
10 s)

MS(ESI<sup>+</sup>) : 336[M+H]<sup>+</sup>, 358[M+Na]<sup>+</sup>

IR(KBr) : 3154, 1679, 1597, 1535, 1444 cm<sup>-1</sup>

m.p. : >250°C (EtOAc)

Example 5

15 3-Amino-6-(6-oxo-1-propyl-1,6-dihydro-3-pyridyl)-  
5-phenyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner  
to that of Preparation 3.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.77 (3H, t, J=7.4 Hz), 1.52 (2H, m),  
20 3.76 (2H, t, J=7.2 Hz), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47  
(8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)

MS(ESI<sup>+</sup>) : 350[M+H]<sup>+</sup>, 372[M+Na]<sup>+</sup>

IR(KBr) : 3421, 1650, 1571, 1515, 1417cm<sup>-1</sup>

m.p. : >250°C (EtOAc)

25 Example 6

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (92.1 mg) was dissolved in DMF (1 ml). To the solution were added 1M *i*-PrI solution in DMF (0.33 ml) and 0.1M *t*-BuOK solution in DMF (3.3 ml). The mixture 5 was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO<sub>4</sub>. Evaporation of solvent gave oily residue. The 10 above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=96 : 4, v/v) to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (18 mg) and 3-amino-6-(6-isopropoxy-3-pyridyl)-5-phenyl-2-pyrazine-15 carboxamide (42 mg).

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)

20 MS (ESI<sup>+</sup>) : 350 [M+H]<sup>+</sup>, 372 [M+Na]<sup>+</sup>

IR (KBr) : 3417, 1664, 1591, 1533, 1450 cm<sup>-1</sup>

m.p. : 240-245°C (EtOAc)

3-Amino-6-(6-isopropoxy-3-pyridyl)-5-phenyl-2-pyrazine-25 carboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.26 (6H, d, J=6.8 Hz), 5.20 (1H, m),  
6.60 (1H, d, J=8.6 Hz), 7.42 (5H, s), 7.60-7.67 (3H, m),  
8.17 (2H, s)

MS (ESI<sup>+</sup>) : 350 [M+H]<sup>+</sup>, 372 [M+Na]<sup>+</sup>

5 IR (KBr) : 3471, 1683, 1656, 1600, 1488 cm<sup>-1</sup>

Example 7

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-  
2-pyrazinecarbonitrile (800 mg) was dissolved in dioxane  
and conc. HCl. The solution was stirred at 80°C for 15 hours.  
10 Dioxane was evaporated out. The reaction mixture was cooled  
to room temperature and concentrated in vacuo to give  
residue. To the residue was added 1N NaOH to adjust the pH  
of the aqueous mixture to 6-7. The crystals were collected  
by filtration, and dried in vacuo to give 3-amino-6-(6-oxo-  
15 1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic  
acid as powder (600 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 6.18 (1H, d, J=9.4 Hz), 7.25-7.65 (9H,  
m), 11.8 (2H, brs)

MS (ESI<sup>-</sup>) : 307 [M-H]<sup>-</sup>

20 Example 8

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-  
2-pyrazinecarboxylic acid (154 mg) was dissolved in DMF (5  
ml). To the solution were added EtI (86.1 mg) and t-BuOK  
(61.9 mg). The mixture was stirred at 20-30°C for 2 hours.  
25 The reaction mixture was portioned EtOAc and water. The

organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO<sub>4</sub>. Evaporation of solvent gave oily residue. The above residue was purified 5 by chromatography on silica gel (EtOAc only - EtOAc : MeOH=95 : 5, v/v) to give ethyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (84 mg) and ethyl 3-amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (28 mg).

10 Ethyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate  
<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.34 (3H, t, J=7.0 Hz), 4.37 (2H, q, J=7.0 Hz), 6.23 (1H, d, J=9.4 Hz), 7.19 (1H, d, J=2.4 Hz), 7.25 (1H, dd, J=2.4, 9.4 Hz), 7.40-7.52 (5H, m)

15 MS(ESI<sup>+</sup>) : 359[M+Na]<sup>+</sup>  
IR(KBr) : 3400, 1697, 1614, 1434, 1130 cm<sup>-1</sup>  
m.p. : 230-238°C (EtOAc)

Ethyl 3-amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate  
<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.00 (3H, t, J=7.0 Hz), 1.34 (3H, t, J=7.0 Hz), 3.76 (2H, q, J=7.0 Hz), 4.37 (2H, q, J=7.0 Hz), 6.32 (1H, d, J=9.4 Hz), 7.32 (1H, dd, J=2.6, 9.4 Hz), 7.36-7.5 (8H, m)

20 MS(ESI<sup>+</sup>) : 365[M+H]<sup>+</sup>, 387[M+Na]<sup>+</sup>  
IR(KBr) : 3400, 1662, 1600, 1440, 1122 cm<sup>-1</sup>

m.p. : 175-179°C (EtOAc)

Example 9

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (283 mg) was dissolved in DMF (10 ml). To the solution were added *i*-PrI (172 mg) and *t*-BuOK (114 mg). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO<sub>4</sub>. Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=96 : 4, v/v) to give isopropyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate as yellow crystal (64mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.35 (6H, d, J=6.2 Hz), 5.20 (1H, m), 6.23 (1H, d, J=9.4 Hz), 7.19 (1H, d, J=2.2 Hz), 7.22 (1H, dd, J=2.2, 9.4 Hz), 7.40 (5H, m), 11.6 (1H, s)  
MS (ESI<sup>+</sup>) : 351[M+H]<sup>+</sup>, 373[M+Na]<sup>+</sup>  
IR (KBr) : 3425, 1666, 1612, 1434, 1101 cm<sup>-1</sup>  
m.p. : 250-256°C (EtOAc)

Example 10

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (370 mg) was dissolved in 1,2-dichloroethane (37 ml). To the solution was added 1M

boron tribromide solution in  $\text{CH}_2\text{Cl}_2$  (12.2 ml). The mixture was stirred at 80°C for 24 hours. The mixture was cooled to 20-25°C, and portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with

5 EtOAc. The combined organic layer was washed with brine, and dried over  $\text{MgSO}_4$ . Evaporation of solvent in vacuo gave reddish solid residue. The residue was pulverized with water, to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile as powder (254 mg).

10  $^1\text{H-NMR}(\text{DMSO-d}_6 \delta)$  : 6.21 (1H, d,  $J=9.4$  Hz), 7.20-7.98 (7H, m), 11.6 (1H, s)

MS (ESI $^+$ ) : 312 [M+Na] $^+$

IR (KBr) : 3326, 2221, 1656, 1610, 1544, 1201  $\text{cm}^{-1}$

m.p. : 243-248°C ( $\text{H}_2\text{O}$ )

15 Example 11

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (58 mg) was dissolved in DMF (1 ml).

To the solution were added 1M MeI solution in DMF (0.22 ml) and 0.1M *t*-BuOK solution in DMF (2.2 ml). The mixture was 20 stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over  $\text{MgSO}_4$ . Evaporation of solvent gave oily residue. The above residue 25 was purified by chromatography on silica gel (EtOAc only

- EtOAc : MeOH=93 : 7, v/v) to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazine-carbonitrile, which was crystallized from EtOAc (18 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.40 (3H, s), 6.17 (1H, d, J=9.4 Hz),

5 6.97 (1H, dd, J=2.6, 9.4 Hz), 7.40-7.50 (7H, m), 7.81 (1H, d, J=2.6 Hz)

MS(ESI<sup>+</sup>) : 304[M+H]<sup>+</sup>, 326[M+Na]<sup>+</sup>

IR(KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm<sup>-1</sup>

m.p. : >250°C (EtOAc)

10 Example 12

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Example 11.

15 <sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.03 (3H, t, J=7.0 Hz), 3.79 (2H, q, J=7.0 Hz), 6.25 (1H, d, J=9.4 Hz), 7.19 (1H, dd, J=2.6, 9.4 Hz), 7.44-7.47 (7H, m), 7.58 (1H, d, J=2.6 Hz)

MS(ESI<sup>+</sup>) : 318[M+H]<sup>+</sup>, 340[M+Na]<sup>+</sup>

IR(KBr) : 3180, 2221, 1657, 1587, 1535, 1203 cm<sup>-1</sup>

20 m.p. : 193-199°C (IPE)

Example 13

3-Amino-6-(6-oxo-1-propyl-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (17 mg)

The title compound was obtained in a similar manner

25 to that of Example 11.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.71 (3H, t, J=7.4 Hz), 1.44 (2H, m), 3.73 (2H, t, J=7.2 Hz), 6.26 (1H, d, J=9.4 Hz), 7.20 (1H, dd, J=2.6, 9.4 Hz), 7.38-7.47 (7H, m), 7.54 (1H, d, J=2.6 Hz)

5 MS(ESI<sup>+</sup>) : 332[M+H]<sup>+</sup>, 354[M+Na]<sup>+</sup>

IR(KBr) : 3311, 2220, 1658, 1536, 1463, 1201 cm<sup>-1</sup>  
m.p. : 180-183°C (IPE)

Example 14

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
10 5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner  
to that of Example 11.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=6.8 Hz), 4.85-4.92 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.28 (1H, d, J=2.4 Hz), 7.38-7.49  
15 (8H, m)

MS(ESI<sup>+</sup>) : 332[M+H]<sup>+</sup>, 354[M+Na]<sup>+</sup>

IR(KBr) : 3426, 2225, 1664, 1621, 15521, 1106 cm<sup>-1</sup>  
m.p. : 204.5°C (95% aq. 2-propanol)

Example 15

20 3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-  
2-pyrazinecarbonitrile (100 mg) was dissolved in 30%  
hydrogen bromide solution in AcOH (1 ml). The solution was  
stirred at 25-30°C for 3 hours. To the solution was added  
water. The pH of the aqueous mixture was adjusted to 6-7  
25 with 12% aq. NaOH. The crystals were precipitated. The

suspension was stirred at 25-30°C for 3 hours, and stood for 10 hours in refrigerator. The crystals was collected by filtration and dried in vacuo, to give 3-amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide 5 (92.5 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.82 (3H, s), 6.69 (1H, d, J=6.6 Hz), 7.39 (5H, s), 7.64-7.70 (3H, m), 8.17 (2H, s)

MS(ESI<sup>+</sup>) : 322[M+H]<sup>+</sup>, 344[M+Na]<sup>+</sup>

IR(KBr) : 3411, 3276, 1689, 1598, 1496, 1286 cm<sup>-1</sup>

10 m.p. : 208-212°C (H<sub>2</sub>O)

The following 24 compounds were obtained in a similar manner to that of Example 1.

#### Example 16

3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-15 5-phenyl-2-pyrazinecarboxamide

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J=9.4 Hz), 7.34-7.46 (6H, m), 7.66-7.72 (4H, m), 8.19 (1H, s)

MS(ESI<sup>+</sup>) : 350[M+H]<sup>+</sup>, 372[M+Na]<sup>+</sup>

20 IR(KBr) : 3417, 1664, 1590, 1533, 1450 cm<sup>-1</sup>

mp : 245°C (IPA-H<sub>2</sub>O)

#### Example 17

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

25 <sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.93 (6H, d, J=6.8 Hz), 4.89 (1H, m),

6.35 (1H, d,  $J=9.4$  Hz), 7.22-7.81 (9H, m), 8.22 (1H, s)

MS (ESI $^+$ ) : 368 [M+H] $^+$ , 390 [M+Na] $^+$

IR (KBr) : 3367, 1664, 1600, 1446, 1205  $\text{cm}^{-1}$

mp : 251.7°C (IPA-H<sub>2</sub>O)

5 Example 18

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-  
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 1.01 (6H, d,  $J=6.8$  Hz), 4.93 (1H, m),  
6.35 (1H, d,  $J=9.4$  Hz), 7.21-7.71 (9H, m), 8.22 (1H, s)

10 MS (ESI $^+$ ) : 368 [M+H] $^+$ , 390 [M+Na] $^+$

IR (KBr) : 3394, 1658, 1590, 1533, 1452  $\text{cm}^{-1}$

mp : 258.8°C (IPA-H<sub>2</sub>O)

Example 19

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-

15 1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 0.97 (6H, d,  $J=6.8$  Hz), 4.90 (1H, m),  
6.32 (1H, d,  $J=9.4$  Hz), 7.34-7.46 (6H, m), 7.66-7.72 (3H,  
m), 8.19 (1H, s)

MS (ESI $^+$ ) : 390 [M+Na] $^+$

20 IR (KBr) : 3293, 1660, 1583, 1450, 1153  $\text{cm}^{-1}$

mp : 235.6°C (IPA-H<sub>2</sub>O)

Example 20

3-Amino-5-(2-chlorophenyl)-6-(1-isopropyl-6-oxo-  
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

25 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 0.90 (6H, m), 4.87 (1H, m), 6.34 (1H,

d, J=9.4 Hz), 7.16 (1H, d, J=2.4 Hz), 7.48-7.68 (6H, m), 7.73 (1H, s), 7.82 (1H, dd, J=2.4, 9.4 Hz), 8.24 (1H, s)

MS (ESI<sup>+</sup>) : 384 [M+H]<sup>+</sup>, 406 [M+Na]<sup>+</sup>

IR (KBr) : 3367, 1666, 1604, 1454, 1157 cm<sup>-1</sup>

5 mp: 254.5°C (IPA-H<sub>2</sub>O)

Example 21

3-Amino-5-(3-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m),

10 6.35 (1H, d, J=9.4 Hz), 7.35-7.46 (5H, m), 7.49 (2H, s),  
7.57-7.72 (3H, m), 8.21 (1H, s)

MS (ESI<sup>+</sup>) : 384 [M+H]<sup>+</sup>, 406 [M+Na]<sup>+</sup>

IR (KBr) : 3396, 1658, 1589, 1452, 1250 cm<sup>-1</sup>

mp: 232.6°C (IPA-H<sub>2</sub>O)

15 Example 22

3-Amino-5-(4-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.02 (6H, d, J=6.8 Hz), 4.94 (1H, m),

6.34 (1H, d, J=9.4 Hz), 7.40 (1H, d, J=2.4 Hz), 7.49 (6H,  
20 s), 7.65 (1H, dd, J=2.4, 9.4 Hz), 7.70 (1H, s), 8.21 (1H,  
s)

MS (ESI<sup>+</sup>) : 406 [M+Na]<sup>+</sup>

IR (KBr) : 3278, 1664, 1587, 1450, 1093 cm<sup>-1</sup>

mp: 246.2°C (IPA-H<sub>2</sub>O)

25 Example 23

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-methoxyphenyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.89-1.05 (6H, m), 3.48 (3H, s), 4.88

(1H, m), 6.32 (1H, d, J=9.4 Hz), 6.99-7.13 (2H, m), 7.22

5 (1H, d, J=2.4 Hz), 7.37-7.65 (2H, m), 7.59 (2H, brs), 7.66

(1H, s), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.16 (1H, s)

MS (ESI<sup>+</sup>) : 380 [M+H]<sup>+</sup>, 402 [M+Na]<sup>+</sup>

IR (KBr) : 3259, 1662, 1596, 1452, 1259 cm<sup>-1</sup>

mp : 263.1°C (IPA-H<sub>2</sub>O)

10 Example 24

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-methoxyphenyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.01 (6H, d, J=6.8 Hz), 3.71 (3H, s),

4.90 (1H, m), 6.33 (1H, d, J=9.4 Hz), 6.94-7.02 (3H, m),

15 7.30-7.39 (2H, m), 7.65-7.71 (3H, m), 8.19 (1H, s)

MS (ESI<sup>+</sup>) : 380 [M+H]<sup>+</sup>, 402 [M+Na]<sup>+</sup>

IR (KBr) : 3442, 1660, 1581, 1444, 1268 cm<sup>-1</sup>

IR (KBr) : 3442, 1660, 1581, 1444, 1268 cm<sup>-1</sup>

mp : 192.3°C (IPA-H<sub>2</sub>O)

20 Example 25

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(4-methoxyphenyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.05 (6H, d, J=6.8 Hz), 3.77 (3H, s),

4.94 (1H, m), 6.32 (1H, d, J=9.4 Hz), 6.97 (2H, d, J=8.8

25 Hz), 7.42 (2H, d, J=8.8 Hz), 7.45-7.64 (5H, m), 8.15 (1H,

s)

MS (ESI<sup>+</sup>) : 380 [M+H]<sup>+</sup>, 402 [M+Na]<sup>+</sup>IR (KBr) : 3266, 1664, 1600, 1448, 1255 cm<sup>-1</sup>mp : 243.9°C (IPA-H<sub>2</sub>O)5 Example 26

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[2-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

1H-NMR (DMSO-d<sub>6</sub> δ) : 0.90 (6H, m), 4.88 (1H, m), 6.34 (1H,

d, J=9.4 Hz), 7.20 (1H, d, J=2.4 Hz), 7.34-7.39 (1H, m),

10 7.54-7.78 (7H, m), 8.24 (1H, s)

MS (ESI<sup>+</sup>) : 434 [M+H]<sup>+</sup>, 456 [M+Na]<sup>+</sup>IR (KBr) : 3386, 1662, 1596, 1257, 1162 cm<sup>-1</sup>mp : 206.5°C (IPA-H<sub>2</sub>O)Example 27

15 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[3-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

1H-NMR (DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=6.8 Hz), 4.88 (1H, m),

6.35 (1H, d, J=9.4 Hz), 7.37-7.81 (9H, m), 8.22 (1H, s)

MS (ESI<sup>+</sup>) : 434 [M+H]<sup>+</sup>, 456 [M+Na]<sup>+</sup>20 IR (KBr) : 3403, 1660, 1592, 1452, 1263 cm<sup>-1</sup>mp : 265.5°C (IPA-H<sub>2</sub>O)Example 28

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[4-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

25 1H-NMR (DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=6.8 Hz), 4.91 (1H, m),

6.37 (1H, d, J=9.4 Hz), 7.30 (1H, d, J=2.4 Hz), 7.42 (2H, d, J=8.2 Hz), 7.58 (2H, d, J=8.2 Hz), 7.70 (3H, m), 7.78 (1H, dd, J=2.4, 9.4 Hz), 8.21 (1H, s)

MS (ESI<sup>+</sup>) : 434 [M+H]<sup>+</sup>, 456 [M+Na]<sup>+</sup>

5 IR (KBr) : 3403, 1660, 1592, 1452, 1263 cm<sup>-1</sup>

mp : 264.0°C (IPA-H<sub>2</sub>O)

Example 29

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

10 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.05 (6H, d, J=6.8 Hz), 4.96 (1H, m), 6.35 (1H, d, J=9.2 Hz), 7.28 (1H, d, J=6.4 Hz), 7.46-7.65 (6H, m), 7.71 (1H, s), 8.21 (1H, s)

MS (ESI<sup>+</sup>) : 386 [M+H]<sup>+</sup>, 408 [M+Na]<sup>+</sup>

IR (KBr) : 3382, 1662, 1602, 1444, 1191 cm<sup>-1</sup>

15 mp : 225.8°C (IPA-H<sub>2</sub>O)

Example 30

3-Amino-5-(3,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

1H-NMR (DMSO-d<sub>6</sub> δ) : 1.05 (6H, d, J=6.8 Hz), 4.95 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.14-7.37 (3H, m), 7.46 (1H, d, J=2.4 Hz), 7.66 (1H, dd, J=2.4, 9.4 Hz), 7.73 (3H, m), 8.23 (1H, s)

MS (ESI<sup>+</sup>) : 408 [M+Na]<sup>+</sup>

IR (KBr) : 3284, 1664, 1587, 1446, 1120 cm<sup>-1</sup>

25 mp : 248.8°C (IPA-H<sub>2</sub>O)

Example 31

3-Amino-5-(4-cyanophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m),

5 6.35 (1H, d, J=9.4 Hz), 7.38 (1H, d, J=2.4 Hz), 7.65 (2H, d, J=8.4 Hz), 7.65-7.69 (4H, m), 7.74 (1H, s), 7.90 (1H, d, J=8.4 Hz), 8.24 (1H, s)

MS(ESI<sup>+</sup>) : 397 [M+Na]<sup>+</sup>

IR(KBr) : 3432, 2223, 1671, 1606, 1450 cm<sup>-1</sup>

10 mp : 292°C (IPA-H<sub>2</sub>O)

Example 32

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=6.8 Hz), 4.89 (1H, m),  
15 6.35 (1H, d, J=9.4 Hz), 7.28 (1H, d, J=2.4 Hz), 7.39-7.49 (8H, m)

MS(ESI<sup>+</sup>) : 332 [M+H]<sup>+</sup>, 354 [M+Na]<sup>+</sup>

IR(KBr) : 3357, 2219, 1652, 1579, 1465, 1203 cm<sup>-1</sup>

mp : 205.4°C (IPA-H<sub>2</sub>O)

20 Example 33

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.91 (6H, d, J=6.8 Hz), 4.87 (1H, m),  
6.37 (1H, d, J=9.4 Hz), 7.18-7.63 (8H, m)

25 MS(ESI<sup>+</sup>) : 350 [M+H]<sup>+</sup>, 372 [M+Na]<sup>+</sup>

IR(KBr) : 3366, 2214, 1615, 1516, 1200  $\text{cm}^{-1}$

mp : 210.6°C (IPA-H<sub>2</sub>O)

Example 34

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-

5 1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m),  
6.37 (1H, d, J=9.4 Hz), 7.22-7.53 (8H, m)

MS(ESI<sup>+</sup>) : 350[M+H]<sup>+</sup>, 372[M+Na]<sup>+</sup>

IR(KBr) : 3360, 2214, 1660, 1570, 1205  $\text{cm}^{-1}$

10 mp : 210.6°C (IPA-H<sub>2</sub>O)

Example 35

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m),  
15 6.37 (1H, d, J=9.4 Hz), 7.22-7.68 (8H, m)

MS(ESI<sup>+</sup>) : 350[M+H]<sup>+</sup>

IR(KBr) : 3364, 2214, 1660, 1572, 1200  $\text{cm}^{-1}$

mp : 207.0°C (IPA-H<sub>2</sub>O)

Example 36

20 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(2-methoxyphenyl)-2-pyrazinecarbonitrile

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.97 (6H, brs), 3.46 (3H, s), 4.86 (1H,  
m), 6.34 (1H, d, J=9.4 Hz), 6.99 (1H, d, 8.2 Hz), 7.10 (1H,  
t, 7.6 Hz), 7.18 (1H, d, 2.5 Hz), 7.37-7.50 (5H, m)

25 MS(ESI<sup>+</sup>) : 362[M+H]<sup>+</sup>, 384[M+Na]<sup>+</sup>

IR(KBr) : 3266, 2214, 1600, 1448, 1255 cm<sup>-1</sup>

mp : 222.6°C (IPA-H<sub>2</sub>O)

Example 37

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-methoxyphenyl)-2-pyrazinecarbonitrile

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=6.8 Hz), 3.69 (3H, s),  
4.91 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.95-6.97 (1H, m),  
7.00 (2H, s), 7.30-7.47 (5H, m)

MS(ESI<sup>+</sup>) : 362 [M+H]<sup>+</sup>, 384 [M+Na]<sup>+</sup>

10 IR(KBr) : 3360, 2215, 1655, 1570, 1205 cm<sup>-1</sup>

mp : 192.3°C (IPA-H<sub>2</sub>O)

Example 38

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(4-methoxyphenyl)-2-pyrazinecarbonitrile

15 <sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.02 (6H, d, J=6.8 Hz), 3.76 (3H, s),  
4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.98 (2H, d, 7.2Hz),  
7.38-7.43 (6H, m)

MS(ESI<sup>+</sup>) : 362 [M+H]<sup>+</sup>, 384 [M+Na]<sup>+</sup>

IR(KBr) : 3357, 2218, 1650, 1570, 1200 cm<sup>-1</sup>

20 mp : 243.9°C (IPA-H<sub>2</sub>O)

Example 39

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

1<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.02 (6H, d, J=6.8 Hz), 4.95 (1H, m),  
6.38 (1H, d, J=9.0 Hz), 7.26 (1H, m), 7.38-7.58 (6H, m),

MS (ESI<sup>+</sup>) : 368 [M+H]<sup>+</sup>, 390 [M+Na]<sup>+</sup>

IR (KBr) : 3166, 2210, 1658, 1461, 1201 cm<sup>-1</sup>

mp : 180°C (IPA-H<sub>2</sub>O)

Example 40

5        3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-  
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (30 g) was  
suspended in dioxane (60 ml) and 2N aq. NaOH (600 ml). The  
mixture was heated at 90°C with stirring for 4 hours. The  
above reaction mixture was cooled to 25-30°C. The pH of the  
10      suspension was adjusted to 2.5 with 35% HCl (105 ml). The  
precipitate was collected by filtration and washed with  
water and dried in vacuo at 50°C for 15 hours to give  
3-amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-  
dihydro-3-pyridyl)-2-pyrazinecarboxylic acid as yellow  
15      powder. (29.6 g)

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m),  
6.37 (1H, d, J=9.4 Hz), 7.22-7.36 (3H, m), 7.48-7.68 (5H,  
m), 13.00 (1H, s)

IR (KBr) : 3266, 1725, 1662, 1600, 1455 cm<sup>-1</sup>

20      mp : 222.2°C (IPA-H<sub>2</sub>O)

Example 41

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-  
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid (25 g)  
was suspended in 1,2-dichlorobenzene (125 ml). The  
25      suspension was heated at 165-170°C with stirring for 4 hours.

The reaction mixture was cooled to 20-25°C. To the cooled mixture was added IPE (250 ml). The suspension was stirred at 25-30°C for 3 hours. The precipitate was collected by filtration and dried in vacuo. The above dried precipitate 5 was purified by chromatography on silica gel (500 g) eluting with CHCl<sub>3</sub> : MeOH (9 : 1, 2 l). Evaporation of solvent in vacuo gave yellowish crystal residue, which was recrystallized from 70% EtOH (322 ml) to give 5-[5-amino-3-(4-fluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)- 10 pyridone as yellowish crystal (19.4 g).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.33 (1H, d, J=9.2 Hz), 6.63 (2H, s), 7.17-7.26 (3H, m), 7.38-7.46 (3H, m), 7.93 (1H, s)

MS(ESI<sup>+</sup>) : 325[M+H]<sup>+</sup>, 347[M+Na]<sup>+</sup>

15 IR(KBr) : 3166, 1666, 1604, 1533, 1467, 1222 cm<sup>-1</sup>

mp : 257.7°C (IPA-H<sub>2</sub>O)

#### Example 42

A mixture of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid 20 (70 mg), methylamine hydrochloride (14.8 mg), 1-ethyl-3-[3'-(dimethylamino)propyl]-carbodiimide (34.1 mg), and 1-hydroxy-benzotriazole (29.7 mg) in CH<sub>2</sub>Cl<sub>2</sub> (0.7 ml) was stirred at 25°C for 4 hours. Water and EtOAc were poured into the mixture. The organic layer was separated, 25 washed with water, sat. aq. NaHCO<sub>3</sub>, and brine, and dried

over  $MgSO_4$ . The solvent was removed under reduced pressure.

The residue was purified by silica-gel column chromatography (*n*-hexane -  $EtOAc$  then  $CH_2Cl_2$  -  $MeOH$ ) and then crystallized from  $MeOH$ -IPE to give

5 3-amino-6-(1-isopropyl-

6-oxo-1,6-dihydro-3-pyridyl)-N-methyl-5-phenyl-  
2-pyrazinecarboxamide (40 mg).

$^1H$ -NMR( $DMSO-d_6$   $\delta$ ) : 0.93 (6H, d,  $J=6.8$  Hz), 2.84 (3H, d,  $J=4.8$  Hz), 4.89 (1H, qq,  $J=6.8, 6.8$  Hz), 6.38 (1H, d,  $J=9.4$  Hz), 7.26 (1H, d,  $J=2.5$  Hz), 7.42 (5H, m), 7.62 (2H, brs), 7.79 (1H, dd,  $J=2.5, 9.4$  Hz), 8.69 (1H, m)

MS(ESI $^+$ ) : 364 [M+H] $^+$

The following 4 compounds were obtained in a similar manner to that of Example 42.

15 Example 43

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
N,N-dimethyl-5-phenyl-2-pyrazinecarboxamide

$^1H$ -NMR( $DMSO-d_6$   $\delta$ ) : 0.93 (6H, d,  $J=6.7$  Hz), 3.04 (3H, s), 3.10 (3H, s), 4.89 (1H, qq,  $J=6.7, 6.7$  Hz), 6.36 (1H, d,  $J=9.4$  Hz), 6.73 (2H, brs), 7.21 (1H, d,  $J=2.5$  Hz), 7.3-7.6 (6H, m)

MS(ESI $^-$ ) : 376 [M-H] $^-$

Example 44

5-[5-Amino-6-(4-morpholinylcarbonyl)-3-phenyl-

25 2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 3.63 (4H, brs), 3.70 (4H, brs), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.4 Hz), 6.78 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.3-7.5 (6H, m)

5 MS (ESI<sup>+</sup>) : 420 [M+H]<sup>+</sup>

Example 45

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-N-(2-pyridylmethyl)-2-pyrazinecarboxamide

10 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=6.8 Hz), 4.64 (2H, d, J=6.0 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.39 (1H, d, J=9.4 Hz), 7.1-7.9 (12H, m), 8.52 (1H, distorted d, J=4.1 Hz), 9.37 (1H, t, J=6.0 Hz).

MS (ESI<sup>+</sup>) : 441 [M+H]<sup>+</sup>

Example 46

15 3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide.

10 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.92 (6H, d, J=6.8 Hz), 4.34 (2H, d, J=5.9 Hz), 4.88 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.4 Hz), 7.24 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.83 (1H, dd, J=2.4, 9.4 Hz), 9.27 (1H, brt, J=5.9 Hz)

20 MS (ESI<sup>+</sup>) : 389 [M+H]<sup>+</sup>, 411 [M+Na]<sup>+</sup>

Example 47

To a mixture of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (70 mg) and NEt<sub>3</sub> (40.4 mg) in THF (0.7 ml), was added

isobutyl chloroformate (32.7 mg) under ice-bath cooling. After 1.5 hours stirring at the same temperature, the mixture was poured into a mixture of sodium borohydride (30.2 mg) in a mixture of THF (0.7 ml) and water (1.4 ml) under ice-bath cooling. After 2.5 hours stirring at the same temperature, the mixture was diluted with water and EtOAc, and then the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was purified by 10 silica-gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub> : MeOH=25 : 1 - 10 : 1). A desired fraction was triturated with IPE to give 5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (24 mg).  
<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 4.59 (2H, d, J=5.6 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 5.34 (1H, t, J=5.6 Hz), 6.3-6.4 (3H, m), 7.20 (1H, d, J=2.4 Hz), 7.2-7.5 (5H, m), 7.50 (1H, dd, J=2.4, 9.4 Hz)  
MS(ESI<sup>+</sup>) : 337[M+H]<sup>+</sup>, 359[M+Na]<sup>+</sup>  
The following 3 compounds were obtained in a similar manner 20 to that of Example 42.

Example 48

5-[5-Amino-6-(1-azetidinylcarbonyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone  
<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.92 (6H, d, J=6.8 Hz), 2.25 (2H, m), 4.09 (2H, t, J=7.6 Hz), 4.70 (2H, t, J=7.6 Hz), 4.91 (1H,  
25

qq,  $J=6.8, 6.8$  Hz), 6.36 (1H, d,  $J=9.4$  Hz), 7.29 (1H, d,  $J=2.4$  Hz), 7.3-7.6 (6H, m), 7.62 (2H, brs)

MS (ESI $^+$ ) : 390 [M+H] $^+$

Example 49

5 3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide  
 $^1$ H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 0.93 (6H, d,  $J=6.8$  Hz), 3.4-3.5 (2H, m), 3.5-3.6 (2H, m), 4.7-5.0 (2H, m), 6.39 (1H, d,  $J=9.4$  Hz), 7.26 (1H, 2.4 Hz), 7.3-7.5 (5H, m), 7.63 (2H, brs),

10 7.75 (1H, dd,  $J=2.4, 9.4$  Hz), 8.63 (1H, t,  $J=5.8$  Hz)

MS (ESI $^+$ ) : 394 [M+H] $^+$ , 416 [M+Na] $^+$

Example 50

3-Amino-N-cyclopropyl-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

15  $^1$ H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 0.6-0.8 (4H, m), 0.93 (6H, d,  $J=6.8$  Hz), 2.84 (1H, m), 4.89 (1H, qq,  $J=6.8, 6.8$  Hz), 6.37 (1H, d,  $J=9.4$  Hz), 7.29 (1H, d,  $J=2.4$  Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.75 (1H, dd,  $J=2.4, 9.4$  Hz), 8.57 (1H, t,  $J=4.2$  Hz)

20 MS (ESI $^+$ ) : 390 [M+H] $^+$ , 412 [M+Na] $^+$

Example 51

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid

The title compound was obtained in a similar manner

25 to that of Example 40.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.31 (1H, d, J=2.4 Hz), 7.2-7.6 (7H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 13.0 (1H, brs)

5 MS(ESI<sup>-</sup>) : 349[M-H]<sup>-</sup>

Example 52

5-(5-Amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner  
10 to that of Example 41.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.32 (1H, d, J=9.4 Hz), 6.60 (2H, brs), 7.21 (1H, d, J=2.4 Hz), 7.2-7.5 (6H, m), 7.93 (1H, s)

MS(ESI<sup>+</sup>) : 307[M+H]<sup>+</sup>, 329[M+Na]<sup>+</sup>

15 Example 53

A mixture of 5-(5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) and N-bromosuccinimide (87.1 mg) in DMF was heated at 50°C with stirring for 20 minutes. Sat. aq. NaHCO<sub>3</sub> and EtOAc were  
20 poured into the mixture. The organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane : EtOAc=10 : 1 - 2 : 1). A desired product was recrystallized with IPE and dried in vacuo to give

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-  
1-isopropyl-2(1H)-pyridone (57 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=6.8 Hz), 4.89 (1H, qq,

J=6.8, 6.8 Hz), 6.97 (2H, brs), 7.24 (1H, d, J=2.4 Hz),

5 7.2-7.6 (5H, m), 7.92 (1H, d, J=2.4 Hz)

MS (ESI<sup>+</sup>) : 463 [M+H]<sup>+</sup>

Example 54

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide

10 The title compound was obtained in a similar manner  
to that of Example 42.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=6.8 Hz), 3.36 (3H, s),  
3.75 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d,  
J=9.3 Hz), 6.79 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.3-7.6

15 (6H, m)

MS (ESI<sup>+</sup>) : 394 [M+H]<sup>+</sup>

Example 55

5-(5-Amino-6-chloro-3-phenyl-2-pyrazinyl)-3-chloro-  
1-isopropyl-2(1H)-pyridone

20 The title compound was obtained in a similar manner  
to that of Example 53.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq,  
J=6.8, 6.8 Hz), 7.05 (2H, brs), 7.22 (1H, d, J=2.4 Hz),  
7.2-7.6 (5H, m), 7.74 (1H, d, J=2.4 Hz)

25 MS (ESI<sup>+</sup>) : 375 [M+H]<sup>+</sup>, 397 [M+Na]<sup>+</sup>

Example 56

5-{5-Amino-6-[(3-methoxy-1-azetidinyl)carbonyl]-3-phenyl-2-pyrazinyl}-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner  
5 to that of Example 1.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=6.8 Hz), 3.24 (3H, s),  
3.8-4.0 (1H, m), 4.2-4.5 (2H, m), 4.4-4.6 (1H, m), 4.8-5.1  
(2H, m), 6.35 (1H, J=9.2 Hz), 7.3-7.5 (7H, m), 7.62 (2H,  
brs)

10 MS(ESI<sup>+</sup>) : 420 [M+H]<sup>+</sup>

Example 57

Under ice-bath cooling, to a suspension of  
3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide (200  
15 mg) in THF (4.0 ml) was added 3.0M solution of  
methylmagnesium chloride in THF (0.85 ml) dropwise. The  
mixture was stirred at the same temperature for 5 hours.  
The mixture was poured into sat. aq ammonium chloride (20  
ml) and an organic layer was extracted with EtOAc (50 ml),  
20 washed with water and brine, and dried over MgSO<sub>4</sub>. The  
solvent was removed under reduced pressure. The residue was  
purified by silica-gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub> :  
MeOH=50 : 1 - 15 : 1). The desired fraction was  
recrystallized from MeOH and dried in vacuo to give  
25 5-(6-acetyl-5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-

2(1H)-pyridone (111 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 2.66 (3H, s),  
 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.4 Hz), 7.30  
 (1H, d, J=2.4 Hz), 7.3-7.6 (5H, m), 7.61 (1H, dd, J=2.4,  
 5 9.4 Hz), 7.81 (2H, brs)

MS(ESI<sup>+</sup>) : 249[M+H]<sup>+</sup>, 371[M+Na]<sup>+</sup>

Example 58

3-Amino-N-[2-(dimethylamino)ethyl]-6-(1-isopropyl-  
 6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-  
 10 2-pyrazinecarboxamide

The title compound was obtained in a similar manner  
 to that of Example 42.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=6.8 Hz), 2.20 (6H, s),  
 2.42 (2H, t, J=6.6 Hz), 3.3-3.5 (2H, m), 4.91 (1H, qq, J=6.8,  
 15 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.31 (1H, d, J=2.4 Hz),  
 7.3-7.5 (5H, m), 7.66 (1H, dd, J=2.4, 9.4 Hz), 8.62 (1H,  
 t, J=5.7 Hz)

MS(ESI<sup>+</sup>) : 421[M+H]<sup>+</sup>

Example 59

20 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-  
 5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner  
 to that of Example 1.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 3.40 (3H, s), 6.17 (1H, d, J=9.4 Hz),  
 25 6.97 (1H, dd, J=2.6, 9.4 Hz), 7.40-7.49 (7H, m), 7.81 (1H,

d,  $J=2.6$  Hz)

MS (ESI $^+$ ) : 304 [M+H] $^+$ , 326 [M+Na] $^+$

IR (KBr) : 3386, 2221, 1670, 1590, 1542, 1205  $\text{cm}^{-1}$

Example 60

5 A mixture of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (500 mg), (4-methoxyphenyl)boronic acid (740 mg), and  $\text{Pd}(\text{PPh}_3)_4$  (56.3 mg) in 2M aq.  $\text{Na}_2\text{CO}_3$  (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and of EtOAc (30 ml) 10 were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine, and dried over  $\text{MgSO}_4$ . After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and 15 eluted with  $\text{CHCl}_3$  : MeOH (25 : 1). The eluent was evaporated and the residue was suspended with IPE and filtrated to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide (512 mg) as a yellow powder.

20  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$   $\delta$ ) : 1.05 (6H, d,  $J=7.0$  Hz), 4.94 (1H, sept,  $J=7.0$  Hz), 6.32 (1H, d,  $J=9.5$  Hz), 6.98 (2H, d,  $J=9.0$  Hz), 7.39-7.64 (7H, m), 8.15 (1H, brs).  
MS (ESI $^+$ ) : 380 [M+H] $^+$ , 421 [M+H+MeCN] $^+$

The following 18 compounds were obtained in a similar manner 25 to that of Example 60.

Example 61

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(2-methoxyphenyl)-2-pyrazinecarboxamide

1H-NMR (DMSO-d<sub>6</sub> δ) : 0.89 (6H, brs), 3.48 (3H, s), 4.88 (1H,  
5 sept, J=6.8 Hz), 6.32 (1H, d, J=9.5 Hz), 7.00-7.13 (2H, m),  
7.22 (1H, d, J=2.5 Hz), 7.37-7.79 (6H, m), 8.16 (1H, brs)

Example 62

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(3-methoxyphenyl)-2-pyrazinecarboxamide

10 1H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=7.0 Hz), 3.71 (3H, s),  
4.92 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 6.94-7.02  
(3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (4H, m), 8.20 (1H,  
brs)

Example 63

15 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(2-methylphenyl)-2-pyrazinecarboxamide

1H-NMR (DMSO-d<sub>6</sub> δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s),  
4.85 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 7.11 (1H,  
d, J=2.5 Hz), 7.32 (4H, brs), 7.70 (3H, brs), 7.89 (1H, dd,  
20 J=2.5, 9.5 Hz), 8.23 (1H, brs)

MS (ESI<sup>+</sup>) : 364 [M+H]<sup>+</sup>, 405 [M+H+MeCN]<sup>+</sup>

Example 64

3-Amino-5-(2,3-difluorophenyl)-6-(1-isopropyl-6-oxo-  
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

25 1H-NMR (DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, sept,

J=7.0 Hz), 6.37 (1H, d, J=9.0 Hz), 7.34-7.79 (8H, m), 8.26 (1H, brs)

MS (ESI<sup>+</sup>) : 386 [M+H]<sup>+</sup>, 427 [M+H+MeCN]<sup>+</sup>

Example 65

5 3-Amino-5-(2,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.99 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.0 Hz), 7.24-7.35 (3H, m), 7.65-7.77 (5H, m), 8.23 (1H, brs)

10 MS (ESI<sup>+</sup>) : 386 [M+H]<sup>+</sup>, 427 [M+H+MeCN]<sup>+</sup>

Example 66

3-Amino-5-(2,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.99 (6H, d, J=7.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.24-7.40 (3H, m), 7.48-7.79 (5H, m), 8.25 (1H, brs)

MS (ESI<sup>+</sup>) : 386 [M+H]<sup>+</sup>, 427 [M+H+MeCN]<sup>+</sup>

Example 67

3-Amino-5-(2-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.61 (1H, dd, J=1.1, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55 (1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.79 (2H, brs), 8.09 (1H, brs)

25 MS (ESI<sup>+</sup>) : 340 [M+H]<sup>+</sup>, 381 [M+H+MeCN]<sup>+</sup>

Example 68

3-Amino-5-(3-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.62 (1H, dd, J=2.0, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55 (1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.99 (2H, s), 8.09 (1H, brs)

MS (ESI<sup>+</sup>) : 340[M+H]<sup>+</sup>, 381[M+H+MeCN]<sup>+</sup>

Example 69

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-thienyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.23 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.42 (1H, d, J=9.5 Hz), 7.04-7.06 (1H, m), 7.16-7.17 (1H, m), 7.49 (1H, d, J=2.5 Hz), 7.54 (1H, d, J=2.5 Hz), 7.65 (2H, brs), 7.69 (1H, d, J=5.5 Hz), 7.87 (1H, d, J=2.5 Hz), 8.06 (1H, brs)

MS (ESI<sup>+</sup>) : 356[M+H]<sup>+</sup>, 397[M+H+MeCN]<sup>+</sup>

Example 70

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-thienyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.12 (6H, d, J=7.0 Hz), 4.98 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.0 Hz), 7.12 (1H, dd, J=1.3, 5.0 Hz), 7.54-7.71 (7H, m), 8.14 (1H, brs)

MS (ESI<sup>+</sup>) : 356[M+H]<sup>+</sup>, 397[M+H+MeCN]<sup>+</sup>

25 Example 71

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(5-methyl-2-thienyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.26 (6H, d, J=6.5 Hz), 2.44 (3H, s),  
5.08 (1H, sept, J=6.8 Hz), 6.41 (1H, d, J=9.5 Hz), 6.76 (1H,  
5 d, J=2.5 Hz), 6.98 (1H, d, J=3.5 Hz), 7.47 (1H, d, J=2.5  
Hz), 7.52 (1H, d, J=2.5 Hz), 7.61 (2H, brs), 7.89 (1H, d,  
J=2.5 Hz), 8.01 (1H, brs)

MS (ESI<sup>+</sup>) : 370 [M+H]<sup>+</sup>, 411 [M+H+MeCN]<sup>+</sup>

Example 72

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(1H-pyrazol-4-yl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.23 (6H, d, J=7.0 Hz), 5.06 (1H, sept,  
J=7.0 Hz), 6.40 (1H, d, J=9.5 Hz), 7.50 (1H, dd, J=2.5, 9.5  
Hz), 7.57 (5H, brs), 7.80 (1H, d, J=2.5 Hz), 8.01 (1H, brs),  
15 13.06 (1H, brs)

MS (ESI<sup>+</sup>) : 362 [M+Na]<sup>+</sup>, 701 [2M+Na]<sup>+</sup>

Example 73

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-[(E)-2-phenylvinyl]-2-pyrazinecarboxamide

20 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.32 (6H, d, J=6.5 Hz), 5.12 (1H, sept,  
J=6.5 Hz), 6.50 (1H, d, J=9.5 Hz), 7.20-7.43 (5H, m),  
7.59-7.83 (6H, m), 7.90 (1H, d, J=2.5 Hz), 8.10 (1H, brs)

MS (ESI<sup>+</sup>) : 398 [M+Na]<sup>+</sup>, 773 [2M+Na]<sup>+</sup>

Example 74

25 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

## 5-(3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=7.0 Hz), 4.93 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 7.37-7.46 (3H, m), 7.66-7.75 (4H, m), 8.26 (1H, brs), 8.61-8.64 (2H, m)

5 MS (ESI<sup>+</sup>) : 351 [M+H]<sup>+</sup>, 392 [M+H+MeCN]<sup>+</sup>

Example 75

## 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

## 5-(4-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=7.0 Hz), 4.93 (1H, sept, J=7.0 Hz), 6.35 (1H, d, J=9.5 Hz), 7.42-7.89 (7H, m), 8.23 (1H, brs), 8.57 (1H, dd, J=2.0, 5.0 Hz), 8.64 (1H, d, J=2.0 Hz)

MS (ESI<sup>+</sup>) : 351 [M+H]<sup>+</sup>, 392 [M+H+MeCN]<sup>+</sup>

Example 76

## 15 3-Amino-5-(4-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.46 (3H, s), 6.17 (1H, d, J=9.5 Hz), 7.00 (1H, dd, J=2.5, 9.5 Hz), 7.25 (2H, t, J=9 Hz), 7.51-7.73 (5H, m), 8.15 (1H, d, J=2.5 Hz), 8.27 (1H, brs)

20 MS (ESI<sup>+</sup>) : 362 [M+Na]<sup>+</sup>, 701 [2M+Na]<sup>+</sup>

Example 77

## 3-Amino-5-(2-furyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.50 (3H, s), 6.33 (1H, d, J=9.0 Hz), 6.63 (1H, dd, J=1.8, 3.5 Hz), 6.83 (1H, d, J=3.5 Hz), 7.28

(1H, dd,  $J=2.5, 9.5$  Hz), 7.69-7.79 (4H, m), 8.10 (1H, d,  $J=2.5$  Hz), 8.16 (1H, brs)

MS (ESI $^+$ ) : 334 [M+Na] $^+$

Example 78

5 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-thienyl)-2-pyrazinecarboxamide

$^1$ H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 3.50 (3H, s), 6.35 (1H, d,  $J=9.5$  Hz), 7.04-7.09 (1H, m), 7.19-7.21 (1H, m), 7.35 (1H, dd,  $J=2.5, 9.5$  Hz), 7.66 (1H, brs), 7.70-7.72 (3H, m), 8.12-8.13 (2H,

10 m)

MS (ESI $^+$ ) : 350 [M+Na] $^+$

Example 79

A mixture of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (200 mg), 15 ethynylbenzen (331 mg), NEt<sub>3</sub> (658 mg), triphenylphosphine (17 mg), CuI (6.2 mg), and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (23 mg) in DMF (2 ml) was heated at 80°C for 18 hours. Water (20 ml) and EtOAc (20 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic 20 layer was washed with water and brine, and dried over MgSO<sub>4</sub>. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with CHCl<sub>3</sub> - MeOH (97 : 3). The eluent was evaporated and the residue was suspended with IPE and 25 filtrated to give 3-amino-6-(1-isopropyl-6-oxo-

1, 6-dihydro-3-pyridyl)-5-(phenylethynyl)-  
2-pyrazinecarboxamide (218 mg) as a yellow powder.

MS (ESI<sup>+</sup>) : 396 [M+Na]<sup>+</sup>, 769 [2M+Na]<sup>+</sup>

Example 80

5        A toluene solution of 3-amino-5-chloro-  
6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
2-pyrazinecarboxamide (200 mg),  
2-(tributylstannylyl)pyridine (311 mg), and Pd(PPh<sub>3</sub>)<sub>4</sub> (22.5  
mg) was refluxed for 5 hours. Water (20 ml) and EtOAc (15  
10 ml) were poured into the reaction mixture and the aqueous  
solution was extracted with EtOAc. The organic layer was  
washed with water and brine, and dried over MgSO<sub>4</sub>. After  
filtration, the solvent was removed under reduced pressure.  
The residual solid was placed on a column of silica-gel and  
15 eluted with CHCl<sub>3</sub> - MeOH (97 : 3). The eluent was evaporated  
and the residue was suspended with IPE and filtrated to give  
3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-(2-pyridyl)-2-pyrazinecarboxamide (64 mg) as a yellow  
powder.

20      <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.01 (6H, d, J=6.5 Hz), 4.93 (1H, sept,  
J=6.5 Hz), 6.30 (1H, d, J=9.5 Hz), 7.35-7.46 (2H, m),  
7.59-7.75 (5H, m), 7.96 (1H, dt, J=1.7, 7.8 Hz), 8.24 (1H,  
brs), 8.55 (1H, d, J=4.5 Hz)

MS (ESI<sup>+</sup>) : 351 [M+H]<sup>+</sup>

25      Example 81

To a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide (210 mg) in dioxane (2 ml) was added an aq. NaOH (2M, 4 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2N aq. HCl. The precipitate was collected by filtration and washed with water to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxylic acid (203 mg) as a yellow powder.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.03 (1H, d, J=7 Hz), 3.77 (3H, s), 4.94 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.98 (2H, d, J=9.0 Hz), 7.41-7.56 (6H, m), 12.91 (1H, brs)

MS (ESI<sup>+</sup>) : 381 [M+H]<sup>+</sup>, 422 [M+H+MeCN]<sup>+</sup>

The following 24 compounds were obtained in a similar manner to that of Example 81.

Example 82

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methoxyphenyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 7.01 (1H, d, J=8 Hz), 7.10 (1H, t, J=7.5 Hz), 7.19 (1H, d, J=2.5 Hz), 7.38-7.49 (4H, m), 7.62 (1H, dd, J=2.5, 9.0 Hz), 12.93 (1H, brs)

MS (ESI<sup>+</sup>) : 381 [M+H]<sup>+</sup>, 422 [M+H+MeCN]<sup>+</sup>

Example 83

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-methoxyphenyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.99 (6H, d, J=7 Hz), 3.70 (3H, s), 4.92

5 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 6.95-7.04 (3H, m), 7.30-7.38 (2H, m), 7.50 (2H, brs), 7.58 (1H, dd, J=2.5, 9.0 Hz), 13 (1H, brs)

MS (ESI<sup>+</sup>) : 381 [M+H]<sup>+</sup>, 422 [M+H+MeCN]<sup>+</sup>

Example 84

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-methylphenyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s),

4.85 (1H, t, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.09 (1H, d, J=2.5 Hz), 7.26 - 7.40 (4H, m), 7.49 (2H, brs), 7.73 (1H, dd, J=2.5, 9.5 Hz), 13.05 (1H, brs)

Example 85

3-Amino-5-(2,3-difluorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=3.5 Hz), 4.92 (1H, sept,

20 J=3.5 Hz), 6.40 (1H, d, J=4.7 Hz), 7.30 (1H, d, J=1.1 Hz), 7.34-7.63 (6H, m), 13.20 (1H, brs)

MS (ESI<sup>+</sup>) : 387 [M+H]<sup>+</sup>, 428 [M+H+MeCN]<sup>+</sup>

Example 86

3-Amino-5-(2,4-difluorophenyl)-6-(1-isopropyl-6-oxo-

25 1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=3.4 Hz), 4.92 (1H, sept, J=3.4 Hz), 6.39 (1H, d, J=4.8 Hz), 7.26-7.33 (3H, m), 7.56 (2H, brs), 7.61 (1H, dd, J=1.3, 4.8 Hz), 7.68-7.74 (1H, m), 13.15 (1H, brs)

5 MS (ESI<sup>+</sup>) : 387 [M+H]<sup>+</sup>, 428 [M+H+MeCN]<sup>+</sup>

Example 87

3-Amino-5-(2,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=3.5 Hz), 4.92 (1H, sept, J=3.5 Hz), 6.4 (1H, d, J=4.8 Hz), 7.25-7.38 (3H, m), 7.51-7.55 (1H, m), 7.58 (2H, brs), 7.62 (1H, dd, J=1.3, 4.8 Hz), 13.19 (1H, brs)

MS (ESI<sup>+</sup>) : 387 [M+H]<sup>+</sup>, 428 [M+H+MeCN]<sup>+</sup>

Example 88

15 3-Amino-5-(2-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.24 (6H, d, J=6.5 Hz), 5.09 (1H, sept, J=6.5 Hz), 6.43 (1H, d, J=9 Hz), 6.62 (1H, dd, J=2, 3.5 Hz), 6.77 (1H, d, J=3 Hz), 7.45-7.51 (3H, m), 7.75-7.82 (2H, m)

20 Example 89

3-Amino-5-(3-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.21 (6H, d, J=3.5 Hz), 5.06 (1H, sept, J=3.5 Hz), 6.43 (1H, d, J=4.8 Hz), 6.54 (1H, d, J=0.9 Hz), 7.44 (2H, brs), 7.48 (1H, dd, J=1.3, 4.8 Hz), 7.72-7.77 (3H,

m), 12.95 (1H, brs)

MS (ESI<sup>+</sup>) : 341 [M+H]<sup>+</sup>, 382 [M+H+MeCN]<sup>+</sup>

Example 90

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-thienyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.22 (6H, d, J=7.0 Hz), 5.08 (1H, sept, J=7.0 Hz), 6.46 (1H, d, J=9.0 Hz), 7.05-7.09 (1H, m), 7.2 (1H, dd, J=1.0, 4.0 Hz), 7.42-7.48 (3H, m), 7.73 (1H, dd, J=1.0, 5.0 Hz), 7.83 (1H, d, J=2.5 Hz), 13.00 (1H, brs)

MS (ESI<sup>+</sup>) : 357 [M+H]<sup>+</sup>, 398 [M+H+MeCN]<sup>+</sup>

Example 91

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-thienyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.10 (6H, d, J=6.5 Hz), 4.98 (1H, sept, J=6.5 Hz), 6.37-6.43 (1H, m), 7.13 (1H, dd, J=1.5, 5.0 Hz), 7.46-7.60 (5H, m), 7.72 (1H, dd, J=1.3, 3 Hz)

MS (ESI<sup>+</sup>) : 357 [M+H]<sup>+</sup>, 398 [M+H+MeCN]<sup>+</sup>

Example 92

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(5-methyl-2-thienyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.25 (6H, d, J=7.0 Hz), 5.09 (1H, sept, J=7.0 Hz), 2.44 (3H, s), 6.45 (1H, d, J=9.5 Hz), 6.77-6.78 (1H, m), 7.01 (1H, d, J=3.5 Hz), 7.40-7.46 (3H, m), 7.85 (1H, d, J=2.5 Hz), 12.98 (1H, brs)

MS (ESI<sup>+</sup>) : 371 [M+H]<sup>+</sup>, 412 [M+H+MeCN]<sup>+</sup>

Example 93

3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(1*H*-pyrazol-4-yl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.23 (1H, d, J=7.0 Hz), 5.07 (1H, sept,

5 J=7.0 Hz), 6.44 (1H, d, J=9.0 Hz), 7.37 (2H, brs), 7.43 (1H, dd, J=2.5, 9.0 Hz), 7.66 (2H, s), 7.77 (1H, d, J=2.5 Hz), 12.99 (1H, brs).

MS (ESI<sup>-</sup>) : 339 [M-H]<sup>-</sup>

Example 94

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[ (E) -2-phenylvinyl]-2-pyrazinecarboxylic acid

MS (ESI<sup>-</sup>) : 375 [M-H]<sup>-</sup>

Example 95

3-Amino-5-(4-fluorophenyl)-6-(1-methyl-6-oxo-1,6-

15 dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.43 (3H, s), 6.22 (1H, d, J=9.5 Hz), 7.05 (1H, dd, J=2.8, 9.5 Hz), 7.26 (2H, t, J=8.8 Hz), 7.50 (2H, brs), 7.55 (2H, dd, J=5.5, 9.0 Hz), 7.92 (1H, d, J=2.5 Hz)

20 Example 96

3-Amino-5-(2-furyl)-6-(1-methyl-6-oxo-1,6-dihydro-

3-pyridyl)-2-pyrazinecarboxylic acid

MS (ESI<sup>-</sup>) : 311 [M-H]<sup>-</sup>

Example 97

25 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-

## 5-(2-thienyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.49 (3H, s), 6.40 (1H, d, J=9.5 Hz),  
 7.08 (1H, dd, J=4.0, 5.0 Hz), 7.22 (1H, dd, J=1.0, 4.0 Hz),  
 7.36 (1H, dd, J=2.8, 9.5 Hz), 7.48 (2H, brs), 7.74 (1H, dd,  
 5 J=1.0, 5.0 Hz), 7.97 (1H, d, J=2.5 Hz)

Example 98

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(phenylethynyl)-2-pyrazinecarboxylic acid

MS (ESI<sup>-</sup>) : 373 [M-H]<sup>-</sup>10 Example 993-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-  
 1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.92 (1H, d, J=7.0 Hz), 4.88 (1H, sept,  
 J=7.0 Hz), 6.38 (1H, d, J=9.5 Hz), 7.18-7.69 (8H, m), 13.12  
 15 (1H, brs)

MS (ESI<sup>+</sup>) : 369 [M+H]<sup>+</sup>, 410 [M+H+MeCN]<sup>+</sup>Example 1003-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-  
 1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

20 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.99 (6H, d, J=6.5 Hz), 4.93 (1H, t,  
 J=6.5 Hz), 6.38 (1H, d, J=9.0 Hz), 7.22-7.60 (8H, m), 13.07  
 (1H, brs)

MS (ESI<sup>+</sup>) : 369 [M+H]<sup>+</sup>, 410 [M+H+MeCN]<sup>+</sup>Example 101

25 3-Amino-5-(3-chlorophenyl)-6-(1-isopropyl-6-oxo-

1, 6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.99 (1H, d, J=7.0 Hz), 4.94 (1H, sept, J=7.0 Hz), 6.39 (1H, d, J=9.5 Hz), 7.37-7.62 (8H, m), 13.06 (1H, brs)

5 MS (ESI<sup>+</sup>) : 385 [M+H]<sup>+</sup>, 426 [M+H+MeCN]<sup>+</sup>

Example 102

3-Amino-5-(4-chlorophenyl)-6-(1-isopropyl-6-oxo-

1, 6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=7.0 Hz), 4.94 (1H, t, J=7.0 Hz), 6.38 (1H, d, J=9.5 Hz), 7.34-7.59 (8H, m), 13.04 (1H, brs)

10 MS (ESI<sup>+</sup>) : 385 [M+H]<sup>+</sup>, 426 [M+H+MeCN]<sup>+</sup>

Example 103

3-Amino-5-(3, 4-difluorophenyl)-6-(1-isopropyl-6-oxo-

15 1, 6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.03 (6H, d, J=7.0 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 7.30-7.61 (7H, m), 13.06 (1H, brs)

20 MS (ESI<sup>+</sup>) : 387 [M+H]<sup>+</sup>, 428 [M+H+MeCN]<sup>+</sup>

Example 104

3-Amino-5-(3, 5-difluorophenyl)-6-(1-isopropyl-6-oxo-

1, 6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.03 (1H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.40 (1H, d, J=9.5 Hz), 7.16-7.59 (7H, m), 13.16

25 (1H, brs)

MS (ESI<sup>+</sup>) : 387 [M+H]<sup>+</sup>, 428 [M+H+MeCN]<sup>+</sup>

Example 105

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-  
5-phenyl-2-pyrazinecarboxylic acid

5     <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.42 (3H, s), 6.18 (1H, d, J=9.0 Hz),  
7.03 (1H, dd, J=2.8, 9.0 Hz), 7.38-7.53 (7H, m), 7.91 (1H,  
d, J=2.5 Hz)

Example 106

A suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-  
10 dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-  
pyrazinecarboxylic acid in 1,2-dichlorobenzene (3 ml) was  
heated at 200°C and stirred for 4 hours. This reaction  
mixture was cooled to room temperature. To this solution  
was added IPE and stirred at room temperature for 1 hour.  
15     The precipitate was collected by filtration and washed with  
IPE. The residual solid was placed on a column of silica-gel  
and eluted with CHCl<sub>3</sub> - MeOH (20 : 1). The eluent was  
evaporated and the residue was purified by  
recrystallization from EtOH - water to give 5-[5-amino-  
20 3-(4-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-  
pyridone (88 mg) as a pale brown crystal.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.02 (6H, d, J=7.0 Hz), 3.75 (3H, s),  
4.94 (1H, sept, J=7.0 Hz), 6.31 (1H, d, J=9.5 Hz), 6.55 (2H,  
brs), 6.94 (2H, d, J=9.0 Hz), 7.29-7.42 (4H, m), 7.87 (1H,  
25     s)

MS (ESI<sup>+</sup>) : 337 [M+H]<sup>+</sup>, 378 [M+H+MeCN]<sup>+</sup>

The following 24 compounds were obtained in a similar manner to that of Example 106.

Example 107

5 5-[5-Amino-3-(2-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.31 (1H, d, J=9.0 Hz), 6.51 (2H, brs), 6.97-7.10 (3H, m), 7.33-7.51 (3H, m), 7.90 (1H, s)

10 MS (ESI<sup>+</sup>) : 337 [M+H]<sup>+</sup>, 378 [M+H+MeCN]<sup>+</sup>

Example 108

5-[5-Amino-3-(3-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=7.0 Hz), 3.69 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.32 (1H, d, J=9.5 Hz), 6.61 (2H, brs), 6.89-6.95 (3H, m), 7.24-7.33 (3H, m), 7.43 (1H, dd, J=2.5, 9.5 Hz), 7.92 (1H, s)

Example 109

5-[5-Amino-3-(2-methylphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.88 (6H, d, J=6.5 Hz), 1.97 (3H, s), 4.84 (1H, sept, J=6.5 Hz), 6.32 (1H, d, J=9.0 Hz), 6.58 (2H, brs), 7.02 (1H, d, J=2.5 Hz), 7.27 (4H, brs), 7.56 (1H, dd, J=2.5, 9.0 Hz), 7.95 (1H, s)

25 Example 110

5-[5-Amino-3-(2,3-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

1H-NMR (DMSO-d<sub>6</sub> δ) : 0.96 (6H, d, J=7 Hz), 4.91 (1H, sept, J=7 Hz), 6.36 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.2 (1H, 5 d, J=2.5 Hz), 7.3-7.51 (4H, m), 8.01 (1H, s)

MS (ESI<sup>+</sup>) : 343[M+H]<sup>+</sup>, 484[M+H+MeCN]<sup>+</sup>

Example 111

5-[5-Amino-3-(2,4-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

10 1H-NMR (DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.35 (1H, d, J=9.0 Hz), 6.7 (2H, brs), 7.19-7.30 (3H, m), 7.47 (1H, dd, J=2.8, 9.0 Hz), 7.56-7.68 (1H, m), 7.97 (1H, s)

MS (ESI<sup>+</sup>) : 343[M+H]<sup>+</sup>, 384[M+H+MeCN]<sup>+</sup>

15 Example 112

5-[5-Amino-3-(2,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

1H-NMR (DMSO-d<sub>6</sub> δ) : 0.97 (6H, d, J=6.8 Hz), 4.91 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.5 Hz), 6.73 (2H, brs), 20 7.21-7.30 (3H, m), 7.44-7.52 (2H, m), 7.99 (1H, s)

MS (ESI<sup>+</sup>) : 343[M+H]<sup>+</sup>, 384[M+H+MeCN]<sup>+</sup>

Example 113

5-[5-Amino-3-(2-furyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

25 1H-NMR (DMSO-d<sub>6</sub> δ) : 1.22 (6H, d, J=7.0 Hz), 5.06 (1H, sept,

J=7.0 Hz), 6.38 (1H, d, J=9.0 Hz), 6.56 (1H, dd, J=1.8, 3.5 Hz), 6.65-6.66 (1H, m), 7.36 (3H, dd, J=2.8, 9.5 Hz), 7.58 (2H, d, J=2.5 Hz), 7.70 (1H, m), 7.87 (1H, s)  
MS (ESI<sup>+</sup>) : 297 [M+H]<sup>+</sup>, 338 [M+H+MeCN]<sup>+</sup>

5 Example 114

5-[5-Amino-3-(3-furyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.19 (6H, d, J=6.5 Hz), 5.04 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=12.0 Hz), 6.42 (1H, brs), 6.54 (2H, brs), 7.39 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, d, J=2.5 Hz), 7.65-7.69 (2H, m), 7.84 (1H, brs)

MS (ESI<sup>+</sup>) : 297 [M+H]<sup>+</sup>, 338 [M+H+MeCN]<sup>+</sup>

Example 115

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.20 (6H, d, J=6.5 Hz), 5.06 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=9.5 Hz), 6.63 (2H, brs), 6.99-7.04 (2H, m), 7.36 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, dd, J=2.0, 4.5 Hz), 7.68 (1H, d, J=2.0 Hz), 7.84 (1H, s)

MS (ESI<sup>+</sup>) : 313 [M+H]<sup>+</sup>, 354 [M+H+MeCN]<sup>+</sup>

Example 116

5-[5-Amino-3-(3-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.09 (6H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.35 (1H, d, J=9.5 Hz), 6.56 (2H, brs), 7.04 (1H,

dd,  $J=1.3, 5.0$  Hz), 7.38-7.44 (2H, m), 7.51-7.58 (2H, m),  
7.87 (1H, s)

MS (ESI $^+$ ) : 313 [M+H] $^+$ , 354 [M+H+MeCN] $^+$

Example 117

5 5-[5-Amino-3-(5-methyl-2-thienyl)-2-pyrazinyl]-1-  
isopropyl-2(1H)-pyridone  
 $^1$ H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 1.22 (6H, d,  $J=6.5$  Hz), 2.41 (3H, s),  
5.07 (1H, sept,  $J=6.5$  Hz), 6.40 (1H, d,  $J=9.5$  Hz), 6.57 (2H,  
brs), 6.69-6.70 (1H, m), 6.84 (1H, d,  $J=3.5$  Hz), 7.35 (1H,  
dd,  $J=2.5, 9.0$  Hz), 7.70 (1H, d,  $J=2.5$  Hz), 7.79 (1H, s)  
MS (ESI $^+$ ) : 327 [M+H] $^+$ , 368 [M+H+MeCN] $^+$

Example 118

5-[5-Amino-3-(1H-pyrazol-4-yl)-2-pyrazinyl]-1-  
isopropyl-2(1H)-pyridone  
15  $^1$ H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 1.20 (6H, d,  $J=6.5$  Hz), 5.05 (1H, sept,  
 $J=6.5$  Hz), 6.38 (1H, d,  $J=9.0$  Hz), 6.45 (2H, brs), 7.34 (1H,  
dd,  $J=2.5, 9.0$  Hz), 7.50-7.62 (3H, m), 7.77 (1H, s), 12.92  
(1H, brs)  
MS (ESI $^+$ ) : 319 [M+Na] $^+$ , 615 [2M+Na] $^+$

20 Example 119

5-[5-Amino-3-[(E)-2-phenylvinyl]-2-pyrazinyl]-1-  
isopropyl-2(1H)-pyridone  
 $^1$ H-NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 1.30 (6H, d,  $J=7.0$  Hz), 5.13 (1H, sept,  
 $J=7.0$  Hz), 6.49 (1H, d,  $J=9.5$  Hz), 6.58 (2H, brs), 7.16 (1H,  
25 d,  $J=15.6$  Hz), 7.29-7.40 (3H, m), 7.53-7.65 (4H, m), 7.74

(1H, d, J=2.0 Hz), 7.88 (1H, s)

MS (ESI<sup>+</sup>) : 333 [M+H]<sup>+</sup>, 355 [M+Na]<sup>+</sup>, 687 [2M+Na]<sup>+</sup>

Example 120

5-[5-Amino-3-(4-fluorophenyl)-2-pyrazinyl]-1-methyl-

5 2 (1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.40 (3H, s), 6.20 (1H, d, J=9.5 Hz),  
6.62 (2H, brs), 7.01 (1H, dd, J=2.5, 9.5 Hz), 7.21 (1H, t,  
J=8.5 Hz), 7.46 (1H, dd, J=5.5, 8.5 Hz), 7.74 (1H, d, J=2.5  
Hz), 7.90 (1H, s)

10 MS (ESI<sup>+</sup>) : 297 [M+H]<sup>+</sup>, 319 [M+Na]<sup>+</sup>, 615 [2M+Na]<sup>+</sup>

Example 121

5-[5-Amino-3-(2-furyl)-2-pyrazinyl]-1-methyl-2 (1H)-  
pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.46 (3H, s), 6.33 (1H, d, J=9.5 Hz),  
15 6.57 (1H, dd, J=1.5, 3.5 Hz), 6.65-6.68 (3H, m), 7.22 (1H,  
dd, J=2.5, 9.5 Hz), 7.69 (1H, s), 7.78 (1H, d, J=2.5 Hz),  
7.85 (1H, s)

MS (ESI<sup>+</sup>) : 269 [M+H]<sup>+</sup>, 291 [M+Na]<sup>+</sup>, 559 [2M+Na]<sup>+</sup>

Example 122

20 5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-methyl-2 (1H)-  
pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.46 (3H, s), 6.36 (1H, d, J=9.5 Hz),  
6.64 (2H, brs), 6.99-7.07 (2H, m), 7.28 (1H, dd, J=2.5, 9.5  
Hz), 7.60 (1H, d, J=3.5 Hz), 7.82 (1H, s), 7.85 (1H, d, J=2.5  
Hz)

MS (ESI<sup>+</sup>) : 307 [M+Na]<sup>+</sup>, 591 [2M+Na]<sup>+</sup>

Example 123

5-[5-Amino-3-(phenylethynyl)-2-pyrazinyl]-1-isopropyl-  
2(1H)-pyridone

5 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.26 (6H, d, J=7.0 Hz), 5.06 (1H, t,  
J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.43-7.54  
(5H, m), 7.91 (1H, dd, J=2.5, 9.5 Hz), 7.95 (1H, s), 8.17  
(1H, d, J=2.5 Hz)

MS (ESI<sup>+</sup>) : 331 [M+H]<sup>+</sup>, 353 [M+Na]<sup>+</sup>, 683 [2M+Na]<sup>+</sup>

10 Example 124

5-[5-Amino-3-(2-fluorophenyl)-2-pyrazinyl]-1-isopropyl-  
2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.92 (6H, d, J=7.0 Hz), 4.88 (1H, sept,  
J=7.0 Hz), 6.34 (1H, d, J=9.5 Hz), 6.67 (2H, brs), 7.15-7.60  
15 (6H, m), 7.97 (1H, s)

MS (ESI<sup>+</sup>) : 325 [M+H]<sup>+</sup>, 366 [M+H+MeCN]<sup>+</sup>

Example 125

5-[5-Amino-3-(3-fluorophenyl)-2-pyrazinyl]-1-isopropyl-  
2(1H)-pyridone

20 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept,  
J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48  
(6H, m), 7.95 (1H, s)

MS (ESI<sup>+</sup>) : 341 [M+H]<sup>+</sup>, 382 [M+H+MeCN]<sup>+</sup>

Example 126

25 5-[5-Amino-3-(3-chlorophenyl)-2-pyrazinyl]-1-isopropyl-

## 2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)

5 MS (ESI<sup>+</sup>) : 341 [M+H]<sup>+</sup>, 382 [M+H+MeCN]<sup>+</sup>

Example 127

5-[5-Amino-3-(4-chlorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.34 (1H, d, J=9.5 Hz), 6.65 (2H, brs), 7.25 (1H, d, J=2.5 Hz), 7.38-7.48 (5H, m), 7.93 (1H, s)

MS (ESI<sup>+</sup>) : 341 [M+H]<sup>+</sup>, 382 [M+H+MeCN]<sup>+</sup>

Example 128

5-[5-Amino-3-(3,4-difluorophenyl)-2-pyrazinyl]-1-

15 isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.03 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 6.68 (2H, brs), 7.20-7.53 (6H, m), 7.95 (1H, s)

MS (ESI<sup>+</sup>) : 343 [M+H]<sup>+</sup>, 384 [M+H+MeCN]<sup>+</sup>

20 Example 129

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 1.04 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.37 (1H, d, J=9.0 Hz), 6.72 (2H, brs), 7.07-7.46 (5H, m), 7.97 (1H, s)

MS (ESI<sup>+</sup>) : 343 [M+H]<sup>+</sup>, 384 [M+H+MeCN]<sup>+</sup>

Example 130

5-(5-Amino-3-phenyl-2-pyrazinyl)-1-methyl-2(1H)-pyridone

5 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 3.38 (3H, s), 6.16 (1H, d, J=4.8 Hz), 6.60 (2H, brs), 6.99 (1H, dd, J=1.4, 4.8 Hz), 7.36-7.42 (5H, m), 7.72 (1H, d, J=1.4 Hz), 7.90 (1H, s)

Example 131

To a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-pyridyl)-2-pyrazinecarboxamide (52 mg) in dioxane (0.5 ml) was added an aq. NaOH (2M, 1 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2N aq. HCl. This solution was evaporated under reduced pressure to give yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzene (2 ml) was heated at 200°C and stirred for 4 hours. This reaction mixture was cooled to room temperature. To this solution was added IPE and stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with IPE. The residual solid was placed on a column of silica-gel and eluted with CHCl<sub>3</sub> - MeOH - 28% aq. ammonia (15 : 1 : 0.1). The eluent was evaporated and the residue was purified by recrystallization from EtOAc - IPE to give 5-(5-amino-

3-(2-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

(5 mg) as a pale yellow crystal.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.13 (6H, d, J=7.0 Hz), 5.18 (1H, t,

J=7.0 Hz), 6.48 (1H, d, J=9.0 Hz), 7.29-7.38 (3H, m), 7.46

5 (1H, d, J=7.5 Hz), 7.75 (1H, dt, J=1.7, 7.5 Hz), 8.09 (1H,

s), 8.71 (1H, d, J=4.5 Hz)

MS(ESI<sup>+</sup>) : 308[M+H]<sup>+</sup>, 349[M+H+MeCN]<sup>+</sup>

The following 2 compounds were obtained in a similar manner

to that of Example 131.

10 Example 132

5-[5-Amino-3-(3-pyridyl)-2-pyrazinyl]-1-isopropyl-

2(1H)-pyridone

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=7.0 Hz), 4.92 (1H, t,

J=7.0 Hz), 6.35 (1H, d, J=9.5 Hz), 6.71 (2H, brs), 7.3 (1H,

15 d, J=2.5 Hz), 7.38-7.46 (2H, m), 7.79 (1H, dt, J=2.5, 4.0

Hz), 7.97 (1H, s), 8.51 (1H, dd, J=1.5, 5.0 Hz), 8.56 (1H,

d, J=1.5 Hz)

MS(ESI<sup>+</sup>) : 308[M+H]<sup>+</sup>, 349[M+H+MeCN]<sup>+</sup>

Example 133

20 5-[5-Amino-3-(4-pyridyl)-2-pyrazinyl]-1-isopropyl-

2(1H)-pyridone

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.96 (6H, d, J=7.0 Hz), 4.92 (1H, t,

J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.74 (2H, brs), 7.25 (1H,

d, J=2.5 Hz), 7.36-7.48 (3H, m), 7.99 (1H, brs), 8.56-8.59

25 (2H, m)

MS (ESI<sup>+</sup>) : 308 [M+H]<sup>+</sup>, 349 [M+H+MeCN]<sup>+</sup>

Example 134

3-Amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (500 mg), 5 (4-methoxyphenyl)boronic acid (740 mg), and Pd(PPh<sub>3</sub>)<sub>4</sub> (56.3 mg) in 2M aq. Na<sub>2</sub>CO<sub>3</sub> (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with 10 water and brine, and dried over MgSO<sub>4</sub>. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with CHCl<sub>3</sub> - MeOH (97 : 3). The eluent was evaporated and the residue was suspended with IPE and filtrated to give 15 yellow powder. To a suspension of this yellow powder in dioxane (0.5 ml) was added an aq. NaOH (2M, 1 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2N aq. HCl. This solution 20 was evaporated under reduced pressure to give yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzene (2 ml) was heated at 200°C and stirred for 4 hours. This reaction mixture was cooled to room temperature. To this solution was added IPE and stirred at room temperature for 25 1 hour. The precipitate was collected by filtration and

washed with IPE. The residual solid was placed on a column of silica-gel and eluted with  $\text{CHCl}_3 - \text{MeOH}$  (97 : 3). The eluent was evaporated and the residue was purified by GPC (Gel Permeation Chromatography) to give 5-[5-amino-

5 3-(5-chloro-2-thienyl)-2-pyrazinyl]-1-isopropyl-  
2(1H)-pyridone (25 mg) and 5-[5-amino-3-(5'-chloro-2,2'-  
bithien-5-yl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone  
(26 mg) as yellow powder.

5-[5-Amino-3-(5-chloro-2-thienyl)-2-pyrazinyl]-1-  
10 isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$   $\delta$ ) : 1.24 (6H, d,  $J=7.0$  Hz), 5.08 (1H, sept,  
 $J=7.0$  Hz), 6.43 (1H, d,  $J=9.0$  Hz), 6.7 (2H, brs), 6.86 (1H,  
d,  $J=11.4$  Hz), 7.02 (1H, d,  $J=4.0$  Hz), 7.38 (1H, dd,  $J=2.5,$   
 $9.0$  Hz), 7.77 (1H, d,  $J=2.5$  Hz), 7.85 (1H, brs)

15 MS (ESI $^+$ ) : 347 [M+H] $^+$ , 388 [M+H+MeCN] $^+$

5-[5-Amino-3-(5'-chloro-2,2'-bithien-5-yl)-2-  
pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$   $\delta$ ) : 1.24 (6H, d,  $J=6.5$  Hz), 5.09 (1H, sept,  
 $J=6.5$  Hz), 6.44 (1H, d,  $J=9.5$  Hz), 6.69 (2H, brs), 6.93 (1H,  
d,  $J=3.5$  Hz), 7.12-7.21 (3H, m), 7.40 (1H, dd,  $J=2.5, 9.5$   
Hz), 7.78 (1H, d,  $J=2.5$  Hz), 7.85 (1H, s)

MS (ESI $^+$ ) : 429 [M+H] $^+$ , 470 [M+H+MeCN] $^+$

#### Example 135

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-  
25 dihydro-3-pyridyl)-N-methyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Preparation 42.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.98 (6H, d, J=7.0 Hz), 2.84 (3H, d, J=5.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.39 (1H, d, J=9.0 Hz), 7.21-7.78 (8H, m), 8.68 (1H, d, J=5.0 Hz)

MS (ESI<sup>+</sup>) : 382[M+H]<sup>+</sup>, 404[M+Na]<sup>+</sup>, 785[2M+Na]<sup>+</sup>

Example 136

To a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (350 mg) in MeOH (7.0 ml), was added thionyl chloride (0.146 ml) dropwise under ice-bath cooling. After 1 hour stirring at the same temperature, the mixture was allowed to warm to room temperature. The mixture was stirred for 6 hours and then refluxed with stirring for 15 hours. After 15 cooling, the solvent was removed under reduced pressure. Water was poured into the residue and the pH of the mixture was adjusted to 10 with 1N aq. NaOH. A precipitate was isolated by filtration, washed with water, and dried in vacuo to give methyl 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (244 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.91 (6H, d, J=6.8 Hz), 3.89 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.3 Hz), 7.21 (1H, d, J=2.4 Hz), 7.30-7.50 (7H, m), 7.56 (1H, dd, J=2.4, 9.3 Hz)

MS (ESI<sup>+</sup>) : 365 [M+H]<sup>+</sup>, 387 [M+Na]<sup>+</sup>

Example 137

Under ice-bath cooling, methylmagnesium chloride (3M solution, 0.46 ml) was added to a suspension of methyl 5 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (100 mg) in THF (10 ml). After 7.5 hours stirring at the same temperature, sat. aq. ammonium chloride solution (1 ml) was poured into the mixture. Water and EtOAc were poured into the mixture and 10 the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE and dried under reduced pressure to give 5-[5-amino-6-(1-hydroxy-1-methylethyl)-3-phenyl-2-pyrazinyl]-1- 15 isopropyl-2(1H)-pyridone (41 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.93 (6H, d, J=6.8 Hz), 1.56 (6H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 5.76 (1H, brs), 6.37 (1H, d, J=9.3 Hz), 6.59 (2H, brs), 7.17 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.53 (1H, dd, J=2.4, 9.3 Hz)

20 MS (ESI<sup>+</sup>) : 365 [M+H]<sup>+</sup>

Example 138

To a solution of 5-(6-acetyl-5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (82 mg) in THF - MeOH (1 : 1, 2.0 ml), was added sodium borohydride (8.9 mg). 25 The mixture was stirred at room temperature for 4 hours.

1N HCl (0.05 ml) was poured into the mixtre. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue 5 was purified by column chromatography. The desired product was recrystallized from EtOH and dried in vacuo to give 5-[5-amino-6-(1-hydroxyethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (16 mg).

10 <sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.93 (3H, d, J=6.7 Hz), 0.94 (3H, d, J=6.7 Hz), 1.46 (3H, d, J=6.5 Hz), 4.70-5.00 (2H, m), 5.57 (1H, d, J=5.4 Hz), 6.35 (1H, d, J=9.4 Hz), 6.40 (2H, brs), 7.18 (1H, d, J=2.5 Hz), 7.40 (5H, m), 7.53 (1H, dd, J=2.5, 9.4 Hz)

15 MS(ESI<sup>+</sup>) : 351[M+H]<sup>+</sup>

15 Example 139

Under ice-bath cooling, NaH (60% pure, 18 mg) was added to a suspension of 5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (100 mg) in DMF (1.0 ml). After 10 minute stirring, MeI (127 mg) 20 was added to the mixture. After 10 minutes stirring at the same temperature, the mixture was allowed to warm to 25°C. After 3.5 hours stirring, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was 25 removed under reduced pressure and the residue was purified

by column chromatography, triturated with IPE, and dried in vacuo to give 5-[5-amino-6-(methoxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (40 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.93 (6H, d, J=6.7 Hz), 3.36 (3H, s),

5 4.53 (2H, s), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.41 (1H, brs), 7.17 (1H, d, J=2.5 Hz), 7.2-7.5 (4H, m), 7.50 (1H, dd, J=2.5, 9.4 Hz)

MS (ESI<sup>+</sup>) : 351[M+H]<sup>+</sup>, 373[M+Na]<sup>+</sup>

Example 140

10 5-[5-Amino-6-[(benzyloxy)methyl]-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner to that of Preparation 139.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.93 (6H, d, J=6.8 Hz), 4.62 (2H, s),

15 4.67 (2H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.45 (2H, brs), 7.18 (1H, d, J=2.4 Hz), 7.20-7.40 (10H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)

MS (ESI<sup>+</sup>) : 427[M+H]<sup>+</sup>, 449[M+Na]<sup>+</sup>

Example 141

20 Under ice-bath cooling, N-bromosuccinimide (1.83 g) was added to a solution of 5-(5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (3.0 g) in DMF (90 ml). The mixture was stirred at the same temperature for 2 hours. Water and CH<sub>2</sub>Cl<sub>2</sub> were poured into the mixture and 25 the organic layer was separated, washed with sat. aq. sodium

thiosulfate solution, sat. aq.  $\text{NaHCO}_3$  solution, water, and brine, and dried over  $\text{MgSO}_4$ . The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica-gel, toluene -  $\text{EtOAc}$ ),

5 recrystallized from  $\text{EtOH}$ , and dried in vacuo to give 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (3.0 g).

$^1\text{H-NMR}(\text{DMSO-}d_6 \delta)$  : 0.93 (6H, d,  $J=6.8$  Hz), 4.88 (1H, qq,  $J=6.8$ , 6.8 Hz), 6.35 (1H, d,  $J=9.4$  Hz), 6.89 (2H, brs), 7.20 (1H, d,  $J=2.5$  Hz), 7.30-7.50 (6H, m)  
10 MS (ESI $^+$ ) : 385[M+H] $^+$ , 407[M+Na] $^+$

Example 142

To a suspension of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) and 15  $\text{Pd}(\text{PPh}_3)_4$  (15 mg) in THF (1.0 ml), was added a solution of methylzinc chloride in THF (2.0M, 0.75 ml). The mixture was stirred at 25°C for 7.5 hours and then heated at 60°C for 1.5 hours. After cooling,  $\text{EtOAc}$  and water were poured into the mixture, and the organic layer was separated, washed 20 with water and brine, and dried over  $\text{MgSO}_4$ . The solvent was removed under reduced pressure. The residue was crystallized from  $\text{MeOH}$  - IPE and dried in vacuo to give 5-(5-amino-6-methyl-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (95 mg).

25  $^1\text{H-NMR}(\text{DMSO-}d_6 \delta)$  : 0.94 (6H, d,  $J=6.8$  Hz), 2.38 (3H, s),

4.89 (1H, qq,  $J=6.8, 6.8$  Hz), 6.33 (1H, d,  $J=9.4$  Hz), 6.38 (2H, s), 7.15 (1H, d,  $J=2.4$  Hz), 7.20-7.50 (5H, m), 7.49 (1H, dd,  $J=2.4, 9.4$  Hz)

MS (ESI $^+$ ) : 321 [M+H] $^+$ , 343 [M+Na] $^+$

5 Example 143

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), phenylboronic acid (79 mg),  $Pd(PPh_3)_4$  (9 mg), a solution of  $Na_2CO_3$  (110 mg) in water (0.8 ml) and dioxane (2.0 ml) 10 was heated at 90°C with stirring for 1 hour. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over  $MgSO_4$ . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE 15 and dried in vacuo to give 5-(5-amino-3,6-diphenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (84 mg).

$^1H$ -NMR (DMSO-d<sub>6</sub>  $\delta$ ) : 0.94 (6H, d,  $J=6.8$  Hz), 4.90 (1H, qq,  $J=6.8, 6.8$  Hz), 6.30-6.40 (3H, m), 7.24 (dH, d,  $J=2.0$  Hz), 7.30-7.70 (9H, m), 7.80-7.90 (2H, m) 20 MS (ESI $^+$ ) : 383 [M+H] $^+$ , 405 [M+Na] $^+$

Example 144

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner 25 to that of Preparation 143.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 6.60-6.80 (3H, m), 7.19 (1H, d, J=3.4 Hz), 7.27 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 7.89 (1H, d, J=1.1 Hz)

MS (ESI<sup>+</sup>) : 373[M+H]<sup>+</sup>, 395[M+Na]<sup>+</sup>

Example 145

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg),  
10 acrylamide (55 mg), Pd(OAc)<sub>2</sub> (3 mg), tris(2-methylphenyl)phosphine (8 mg), NEt<sub>3</sub> (0.11 ml), and DMF (1.0 ml) was heated with stirring at 60°C for 1 hour and then at 90°C for 5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was 15 separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was recrystallized from EtOAc and dried in vacuo to give (2E)-3-[3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinyl]acrylamide 20 (70 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.93 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.40 (1H, d, J=9.4 Hz), 6.81 (2H, brs), 7.08 (1H, d, J=14.9 Hz), 7.10-7.20 (2H, m), 7.20-7.50 (5H, m), 7.62 (1H, dd, J=2.5, 9.3 Hz), 7.70 (1H, brs), 7.75 (1H, d, 25 J=14.9 Hz)

MS (ESI<sup>+</sup>) : 376 [M+H]<sup>+</sup>, 398 [M+Na]<sup>+</sup>

Example 146

(2E)-3-[3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinyl]-N,N-dimethylacrylamide

5 The title compound was obtained in a similar manner to that of Preparation 145.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.96 (6H, d, J=6.7 Hz), 2.96 (3H, s), 3.16 (3H, s), 4.92 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.84 (2H, brs), 7.30-7.60 (8H, m), 7.79 (1H, d,

10 J=14.6 Hz)

MS (ESI<sup>+</sup>) : 404 [M+H]<sup>+</sup>, 426 [M+Na]<sup>+</sup>

Example 147

To a mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (500 mg), 15 ethynyl(trimethyl)silane (255 mg), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (46 mg), CuI (12 mg), and CH<sub>2</sub>Cl<sub>2</sub> (10 ml), was added NEt<sub>3</sub> (0.2 ml) under ice-bath cooling. The mixture was allowed to warm to 25°C and stirred for 15 hours. Water and EtOAc were poured into the mixture, and the organic layer was separated, washed 20 with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica-gel; CH<sub>2</sub>Cl<sub>2</sub> - MeOH), recrystallized from EtOH, and dried in vacuo to give 5-(5-amino-3-phenyl-6-[(trimethylsilyl)ethynyl]-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (373 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.29 (9H, s), 0.94 (6H, d, J=6.7 Hz), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.34 (1H, d, J=9.4 Hz), 6.70 (2H, brs), 7.21 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.47 (1H, dd, J=2.5, 9.4 Hz)

5 MS(ESI<sup>+</sup>) : 403[M+H]<sup>+</sup>, 425[M+Na]<sup>+</sup>

Example 148

A mixture of 5-(5-amino-3-phenyl-6-[(trimethylsilyl)ethynyl]-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (300 mg) and sat. K<sub>2</sub>CO<sub>3</sub> in MeOH (4.5 ml) was 10 stirred at 25°C for 3 hours. Water and EtOAc were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was purified by short column (silica-gel; CH<sub>2</sub>Cl<sub>2</sub>) and 15 recrystallized from EtOH to give 5-(5-amino-6-ethynyl-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.95 (6H, d, J=6.8 Hz), 4.71 (1H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.34 (1H, d, J=9.3 Hz), 6.75 (2H, brs), 7.22 (1H, d, J=2.5 Hz), 7.30-7.50 (6H, m)  
20 MS(ESI<sup>+</sup>) : 331[M+H]<sup>+</sup>, 353[M+Na]<sup>+</sup>

Example 149

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), sodium 25 methoxide (70 mg), CuI (5 mg) in NMP (1.0 ml) was heated

at 100°C for 2.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was 5 recrystallized from MeOH - IPE to give 5-(5-amino-6-methoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (58 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=6.7 Hz), 3.98 (3H, s), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.35 (1H, d, J=9.4 Hz), 6.49 (2H, brs), 7.19 (1H, d, J=9.4 Hz), 7.20-7.40 (5H, m), 7.52 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI<sup>+</sup>) : 337[M+H]<sup>+</sup>, 359[M+Na]<sup>+</sup>

Example 150

A mixture of 5-(5-amino-6-methoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (80 mg), conc. HCl (0.8 ml), and dioxane (1.6 ml) was heated with stirring at 100°C for 3 hours. After cooling, the pH of the mixture was adjusted to 8 and a generated precipitate was isolated by filtration and dried in vacuo to give 5-(5-amino-6-hydroxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (36 mg).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> δ) : 1.08 (6H, d, J=6.8 Hz), 4.94 (1H, qq, J=6.8, 6.8 Hz), 6.26 (1H, d, J=9.4 Hz), 6.76 (2H, brs), 7.13 (1H, dd, J=2.2, 9.4 Hz), 7.1-7.3 (5H, m), 7.46 (1H, d, J=2.2 Hz), 11.91 (1H, brs)

MS (ESI<sup>+</sup>) : 323[M+H]<sup>+</sup>, 345[M+Na]<sup>+</sup>

Example 151

To a solution of phenol (147 mg) in NMP (1.0 ml), was added 60% NaH (52 mg) under ice-bath cooling. After 5 minutes stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) was added to the mixture at the same temperature. And then the mixture was heated at 100°C with stirring for 5.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (88 mg).

15 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) :: 0.90 (6H, d, J=6.8 Hz), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.23 (1H, d, J=10.1 Hz), 7.15 (2H, m), 7.20-7.50 (10H, m)

MS (ESI<sup>+</sup>) : 399[M+H]<sup>+</sup>, 421[M+Na]<sup>+</sup>

Example 152

20 A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) and a solution of methylamine in THF (2.0M, 1.0 ml) was heated at 100°C with stirring for 20 hours in a sealed tube. After cooling, the solvent was removed under reduced pressure and 25 the residue was recrystallized from MeOH - IPE to give

5-[5-amino-6-(methylamino)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (13 mg). The filtrate was concentrated in vacuo, and the residue was rinsed with MeOH - IPE to give the desired product (60 mg).

5  $^1\text{H-NMR}$ (DMSO- $\text{d}_6$   $\delta$ ) : 0.94 (6H, d,  $J=6.7$  Hz), 2.93 (3H, d,  $J=4.4$  Hz), 4.90 (1H, qq,  $J=6.7, 6.7$  Hz), 6.11 (2H, brs), 6.33 (1H, d,  $J=9.3$  Hz), 6.49 (1H, m), 7.19 (1H, d,  $J=2.4$  Hz), 7.10-7.40 (5H, m), 7.52 (1H, dd,  $J=2.4, 9.4$  Hz)  
MS(ESI $^+$ ) : 336[M+H] $^+$ , 358[M+Na] $^+$

10 Example 153

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), morpholine (113 mg), and NMP (1.0 ml) was heated at 150°C with stirring for 1 day. After cooling, EtOAc and water were 15 poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over  $\text{MgSO}_4$ . The solvent was removed under reduced pressure, and the residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-[5-amino-6-(4-morpholiny)-3-phenyl-

20 2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (84 mg).

$^1\text{H-NMR}$ (DMSO- $\text{d}_6$   $\delta$ ) : 0.94 (6H, d,  $J=6.7$  Hz), 3.10-3.20 (4H, m), 3.70-3.90 (4H, m), 4.90 (1H, qq,  $J=6.7, 6.7$  Hz), 6.22 (2H, brs), 6.35 (1H, d,  $J=9.4$  Hz), 7.19 (1H, d,  $J=2.4$  Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd,  $J=2.4, 9.4$  Hz)

25 MS(ESI $^+$ ) : 392[M+H] $^+$ , 414[M+Na] $^+$

Example 154

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), dimethylamine hydrochloride (106 mg),

5 N,N-diisopropylethylamine (201 mg) in NMP (1.0 ml) was heated at 150°C with stirring for 65 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-[5-amino-6-(dimethylamino)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (8 mg).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.94 (6H, d, J=7.0 Hz), 2.83 (6H, s), 4.90 (1H, qq, J=7.0, 7.0 Hz), 6.16 (2H, brs), 6.34 (1H, d, J=9.5 Hz), 7.20 (1H, d, J=2.5 Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, J=2.5, 9.5 Hz)

MS (ESI<sup>+</sup>) : 350[M+H]<sup>+</sup>, 372[M+Na]<sup>+</sup>

Example 155

To a solution of pyrazole (106 mg) in NMP (1.0 ml), 20 was added 60% NaH (52 mg) under ice-bath cooling. After 5 minutes stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) was added to the mixture. And then the mixture was heated at 100°C with stirring for 2 hours. After cooling, EtOAc and 25 water were poured into the mixture, and the organic layer

was separated, washed with water and brine, and dried over  $MgSO_4$ . The solvent was removed under reduced pressure, and the residue was recrystallized from  $MeOH$  and dried in vacuo to give 5-[5-amino-3-phenyl-6-(1*H*-pyrazol-1-yl)-

5 2-pyrazinyl]-1-isopropyl-2(*1H*)-pyridone (60 mg).

$^1H$ -NMR(DMSO- $d_6$   $\delta$ ) : 0.98 (6H, d,  $J=6.8$  Hz), 4.92 (1H, qq,  $J=6.8$ , 6.8 Hz), 6.38 (1H, d,  $J=9.4$  Hz), 6.68 (1H, m), 7.3-7.5 (6H, m), 7.5-7.7 (3H, m), 7.94 (1H, m), 8.78 (1H, m)

MS(ESI $^-$ ) : 371[M-H] $^-$

10 Example 156

5-[5-amino-3-phenyl-6-(1*H*-pyrrol-1-yl)-2-pyrazinyl]-1-isopropyl-2(*1H*)-pyridone

The title compound was obtained in a similar manner to that of Preparation 155.

15  $^1H$ -NMR(DMSO- $d_6$   $\delta$ ) : 0.95 (6H, d,  $J=6.8$  Hz), 4.90 (1H, qq,  $J=6.8$ , 6.8 Hz), 6.3-6.4 (3H, m), 6.49 (2H, brs), 7.28 (1H, d,  $J=2.4$  Hz), 7.30-7.50 (7H, m), 7.53 (1H, dd,  $J=2.4$ , 9.4 Hz)

MS(ESI $^+$ ) : 372[M+H] $^+$ , 394[M+Na] $^+$

20 Example 157

To a suspension of 60%  $NaH$  (52 mg) in NMP (1.0 ml), was added thiophenol (143 mg) under ice-bath cooling. After 10 minute stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(*1H*)-pyridone (100 mg) was

25 added to the mixture at the same temperature. The mixture

was stirred at the same temperature for 10 minutes and then allowed to warm to 25°C. After 2 hours stirring, the mixture was heated at 100°C for 1 hour. After cooling, EtOAc and water were poured into the mixture, and the organic layer 5 was separated, washed with water and brine, and dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-[5-amino-3-phenyl-6-(phenylthio)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (93 mg).

10 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub> δ) : 0.93 (6H, d, J=6.8 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.18 (1H, d, J=9.4 Hz), 6.62 (2H, brs), 7.06 (1H, dd, J=2.4, 9.4 Hz), 7.17 (1H, d, J=2.4 Hz), 7.3-7.5 (8H, m), 7.5-7.6 (2H, m)


MS (ESI<sup>+</sup>) : 415 [M+H]<sup>+</sup>, 437 [M+Na]<sup>+</sup>

## CLAIMS

1. A pyrazine derivative shown by the following formula


(I):

5



wherein

10



wherein

15

R<sup>6</sup> is hydrogen, or optionally substituted lower alkyl;

R<sup>7</sup> is hydrogen or halogen;

R<sup>8</sup> is lower alkyl;

R<sup>2</sup> is hydrogen; hydroxy; halogen; cyano; or lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by

20

substituent(s);


R<sup>3</sup> and R<sup>4</sup> are independently hydrogen, lower alkyl or acyl; and

25

R<sup>5</sup> is lower alkyl, lower alkenyl, lower alkynyl, cyano, aryl or heterocyclic group, each of which is optionally substituted by substituent(s);

or a salt thereof.

2. The compound of claim 1, wherein



wherein

R<sup>6</sup> is hydrogen, lower alkyl, aryl(lower)alkyl,  
heteroaryl(lower)alkyl;

R<sup>7</sup> is hydrogen or halogen;

10     R<sup>2</sup> is hydrogen, halogen, cyano, optionally substituted  
lower alkyl, optionally substituted lower alkynyl,  
lower alkoxy, aryloxy, arylthio, carbamoyl,  
carboxy, protected carboxy or optionally  
substituted amino;

15     R<sup>3</sup> and R<sup>4</sup> are independently hydrogen or lower alkyl;  
and

R<sup>5</sup> is aryl or heteroaryl each of which is optionally  
substituted by one or more substituent(s);

or a salt thereof.

20     3. The compound of claim 2, wherein

R<sup>2</sup> is hydrogen, halogen, cyano,  
hydroxylated(lower)alkyl, lower alkynyl, lower  
alkoxy, aryloxy, arylthio, carboxy, esterified  
carboxy, carbamoyl, amidated carboxy, amino or  
25     mono- or di-(lower)alkylamino;

$R^3$  and  $R^4$  are independently hydrogen;

$R^5$  is aryl or heteroaryl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of halogen and lower alkoxyl;

$R^6$  is hydrogen or lower alkyl; and

$R^7$  is hydrogen;

or a salt thereof.

4. The compound of claim 3, wherein

$R^2$  is hydrogen, bromo, cyano, hydroxymethyl, hydroxyethyl, hydroxypropyl, ethynyl, methoxy, ethoxy, propoxy, phenoxy, phenylthio, carboxy, carbamoyl, mono- or di-methylaminocarbonyl, pyridylmethyaminocarbonyl, hydroxymethylaminocarbonyl or mono- or di-methylamino;

$R^3$  and  $R^4$  are independently hydrogen;

$R^5$  is phenyl, pyridyl, furyl, thiophenyl, pyrrolyl or pyrazolyl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of fluoro, chloro and methoxy;

$R^6$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl or *t*-butyl; and

$R^7$  is hydrogen;

or a salt thereof.

5. The compound of claim 4, wherein  
 $R^2$  is hydrogen, cyano, ethynyl, methoxy, phenoxy,  
 phenylthio, carboxy, carbamoyl or methylamino;  
 and

5 R<sup>5</sup> is phenyl, furyl or thienyl, each of which is  
 optionally substituted by one or more  
 substituent(s) selected from the group consisting  
 of fluoro, chloro and methoxy;  
 or a salt thereof.


10 6. The compound of claim 5, wherein

$R^2$  is hydrogen, cyano, carboxy, carbamoyl or  
 methylamino;

$R^5$  is phenyl which is optionally substituted by one or  
 more fluoro; and


15 R<sup>6</sup> is hydrogen, methyl, ethyl or isopropyl;  
 or a salt thereof.

7. A process for preparing the pyrazine compound of the  
 following formula (I):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined in claim  
 1, or a salt thereof;  
 which comprises

25 (1) reacting of a compound of the formula (II):



wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$  are each as defined above, and

5 Hal is a halogen atom;

or a salt thereof,

with a compound of the formula (III) :



wherein

10  $\text{R}^5$  is as defined above, and

$\text{Z}$  is hydrogen, an alkali metal (e.g. lithium, sodium, potassium, etc.),  $\text{SnBu}_3$ ,  $\text{BW}_2$  or  $\text{Met-Hal}$ ;

wherein  $\text{BW}_2$  is a part of organoboron compound such as  $\text{B}(\text{OH})_2$ ,  $\text{B}(\text{CHCH}_3\text{CH}(\text{CH}_3)_2)_2$ ,

15 tetramethyl-1,3,2-dioxaborolan-2-yl,

9-borabicyclo[3.3.1]nonanyl, or the like;


and

$\text{Met-Hal}$  is a part of metalhalide compound such as

$\text{MgBr}$ ,  $\text{ZnCl}$ , or the like;

20 or a salt thereof,


to give a compound of the formula (I):




25 wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are each as defined above,

or a salt thereof,

(2) hydrolyzing of a compound of the formula (Ia)




wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined above, and  
R<sup>8</sup> is as defined in claim 1, or a salt thereof,  
to give a compound of the formula (Iba):




wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined above, and  
R<sup>9</sup> is cyano, carbamoyl or carboxy;  
or a salt thereof,

15 (3) alkylating to a nitrogen atom of a compound of the  
formula (Ib):



20 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined above, or  
a salt thereof,  
with a compound of the formula (IV):



wherein R<sup>10</sup> is lower alkyl, aryl(lower)alkyl or


25 heteroaryl(lower)alkyl, each of which is

optionally substituted by one or more  
suitable substituent(s), and

Y is a leaving group;


or a salt thereof,

5 to give a compound of the formula (Ic):



10 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>10</sup> are each as defined above, or  
a salt thereof,


(4) hydrolyzing of a compound of the formula (Id):



15

wherein R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined above, or a  
salt thereof,

to give a compound of the formula (Ie):




20

wherein R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined above, or a  
salt thereof,

(5) decarboxylating of a compound (Ie) or a salt thereof

25


above to give a compound of the formula (If):



wherein R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each as defined above, or a

5 salt thereof,

(6) halogenating of a compound (If) or a salt thereof above  
to give a compound of the formula (Ih):



10

wherein R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and Hal are each as defined above, or  
a salt thereof,

(7) reacting of a compound (Ih) or a salt thereof above  
with a compound of the formula (V):

15 R<sup>13</sup>-Z (V)


wherein Z is defined above, and

R<sup>13</sup> is lower alkyl, lower alkenyl, lower alkynyl,  
lower alkoxy, aryloxy, arylthio, acyl, aryl,  
heterocyclic group or amino, each of which is

20 optionally substituted by substituent(s);

or a salt thereof,


to give a compound of the formula (Ij):




25

wherein R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>13</sup> are each as defined above, or a salt thereof,

(8) reacting of a compound of the formula (XI):



wherein R<sup>1</sup> is as defined above, or a salt thereof, with aminomalonitrile, to give a compound of the formula (XII):




wherein R<sup>1</sup> and R<sup>2</sup> are each as defined above, or a salt thereof,

(9) halogenating of a compound of the formula (XV):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each as defined above, or a salt thereof,

20 with a compound of the formula (XVI):



wherein Hal is as defined above,

to give a compound (II) or a salt thereof above.

8. A pharmaceutical composition comprising the compound  
25 of claim 1 or a pharmaceutically acceptable salt thereof

in admixture with a pharmaceutically acceptable carrier.

9. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack and angina pectoris, which comprises administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.
10. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, Meniere's syndrome and cerebral infarction,

which comprises administering any of the compound of claim 1 to 7 or a pharmaceutically acceptable salt thereof to a human being or an animal.

11. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease and anxiety, which comprises administering any of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal
- 10 12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as a medicament.
13. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an adenosine antagonist.
14. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an A<sub>1</sub> receptor and A<sub>2</sub> receptor dual antagonist.
- 15 15. A process for preparing a pharmaceutical composition which comprises admixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.
- 20 16. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition for the therapy of diseases on which an adenosine antagonist is therapeutically effective.

17. A method for evaluation of adenosine antagonism which comprises use of compound of claim 1 or a pharmaceutically acceptable salt thereof.

# INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2004/016193

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/04 C07D401/14 C07D409/14 C07D405/14 A61K31/4965

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 308 441 A (EISAI CO., LTD) 7 May 2003 (2003-05-07) examples 103a; 103b, 182, 183; table page 55, compounds 3-8, table page 60, compounds 112-114; table page 63, compounds 154-156 & WO 02/14282 A (EISAI CO., LTD; HARADA, HITOSHI; ASANO, OSAMU; MIYAZAWA, SHUHEI; UEDA,) 21 February 2002 (2002-02-21) cited in the application	1-17
Y	WO 00/25791 A (SMITHKLINE BEECHAM CORPORATION; ADAMS, JERRY, L; BOEHM, JEFFREY, C; HA) 11 May 2000 (2000-05-11) overlap; claims; pages 5, 11 and 26	1-17
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

17 March 2005

24/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentbaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax. (+31-70) 340-3016

Authorized officer

Frelon, D

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/JP2004/016193

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/60806 A (NEUROGEN CORPORATION; YOON, TAEYOUNG; GE, PING; HORVATH, RAYMOND, F; D) 23 August 2001 (2001-08-23) overlap; pages 1-2; table I page 46, examples 3,10,14; table II page 55, example 46a-c, page 57, example 46j-k, page 59, examples 47m-n; table III page 74, examples 62z	1-17
Y	WO 03/045924 A (PHARMACIA & UPJOHN COMPANY; VERHOEST, PATRICK, R; HOFFMAN, ROBERT, L;) 5 June 2003 (2003-06-05) overlap; pages 6, 73 and 74	1-17
Y	WO 01/62233 A (F. HOFFMANN LA ROCHE AG) 30 August 2001 (2001-08-30) abstract; claims	1-17
A,P	WO 2004/016605 A (FUJISAWA PHARMACEUTICAL CO., LTD; AKAHANE ATSUSHI) 26 February 2004 (2004-02-26) the whole document	1-17
A	US 4 072 746 A (LESHER ET AL) 7 February 1978 (1978-02-07) abstract; claims	1-17
A	US 4 313 951 A (LESHER ET AL) 2 February 1982 (1982-02-02) abstract; claims	1-17

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP2004/016193

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

**Continuation of Box II.1**

Although claims 9-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 17 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
**PCT/JP2004/016193**

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 1308441	A 07-05-2003		AU 7774101 A CA 2417846 A1 EP 1308441 A1 MX PA03001136 A NO 20030637 A US 2004006082 A1 CN 1446202 A WO 0214282 A1 ZA 200300482 A	25-02-2002 30-01-2003 07-05-2003 24-06-2003 10-04-2003 08-01-2004 01-10-2003 21-02-2002 10-05-2004
WO 0214282	A 21-02-2002		AU 7774101 A CA 2417846 A1 CN 1446202 A EP 1308441 A1 WO 0214282 A1 MX PA03001136 A NO 20030637 A US 2004006082 A1 ZA 200300482 A	25-02-2002 30-01-2003 01-10-2003 07-05-2003 21-02-2002 24-06-2003 10-04-2003 08-01-2004 10-05-2004
WO 0025791	A 11-05-2000		AT 258055 T AU 1909200 A DE 69914357 D1 DE 69914357 T2 EP 1126852 A1 ES 2212657 T3 JP 2002528506 T WO 0025791 A1 US 2004014973 A1 US 6548503 B1	15-02-2004 22-05-2000 26-02-2004 11-11-2004 29-08-2001 16-07-2004 03-09-2002 11-05-2000 22-01-2004 15-04-2003
WO 0160806	A 23-08-2001		AU 3849401 A BG 106968 A BR 0108363 A CA 2398937 A1 CN 1400970 A CZ 20022739 A3 EE 200200453 A EP 1255740 A2 EP 1500653 A1 HR 20020747 A2 HU 0301573 A2 JP 2004500383 T MX PA02007868 A NO 20023869 A SK 11542002 A3 WO 0160806 A2 US 2003018035 A1 ZA 200206103 A	27-08-2001 30-04-2003 10-02-2004 23-08-2001 05-03-2003 12-02-2003 15-12-2003 13-11-2002 26-01-2005 31-12-2004 29-12-2003 08-01-2004 10-02-2003 11-09-2002 04-03-2003 23-08-2001 23-01-2003 20-08-2003
WO 03045924	A 05-06-2003		AU 2002343557 A1 BR 0214309 A CA 2467870 A1 EP 1446387 A1 WO 03045924 A1 US 2003144297 A1 US 2005049257 A1	10-06-2003 13-10-2004 05-06-2003 18-08-2004 05-06-2003 31-07-2003 03-03-2005

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
**PCT/JP2004/016193**

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0162233	A 30-08-2001	AU 5464301 A		03-09-2001
		BR 0108611 A		06-05-2003
		CA 2398274 A1		30-08-2001
		CN 1438890 A		27-08-2003
		CZ 20023199 A3		14-05-2003
		WO 0162233 A2		30-08-2001
		EP 1261327 A2		04-12-2002
		HR 20020673 A2		31-12-2004
		HU 0300029 A2		28-05-2003
		JP 2003523380 T		05-08-2003
		MX PA02008240 A		29-11-2002
		NO 20024006 A		22-08-2002
		NZ 520241 A		28-05-2004
		US 2001027196 A1		04-10-2001
		ZA 200206077 A		30-10-2003
WO 2004016605	A 26-02-2004	WO 2004016605 A1		26-02-2004
US 4072746	A 07-02-1978	US 4004012 A		18-01-1977
		AR 220512 A1		14-11-1980
		AR 223137 A1		31-07-1981
		AR 231541 A1		28-12-1984
		AT 362375 B		11-05-1981
		AT 4380 A		15-10-1980
		AT 357534 B		10-07-1980
		AT 48979 A		15-12-1979
		AT 359494 B		10-11-1980
		AT 767476 A		15-04-1980
		AU 1857376 A		20-04-1978
		BE 847196 A1		13-04-1977
		CA 1089860 A1		18-11-1980
		CA 1103253 A2		16-06-1981
		CA 1103254 A2		16-06-1981
		CH 620908 A5		31-12-1980
		CH 619936 A5		31-10-1980
		CH 618969 A5		29-08-1980
		DE 2646469 A1		28-04-1977
		DK 203583 A ,B,		06-05-1983
		DK 455876 A ,B,		15-04-1977
		ES 452405 A1		01-11-1977
		FI 762919 A ,B,		15-04-1977
		FI 65061 B		30-11-1983
		FR 2327779 A1		13-05-1977
		GB 1512129 A		24-05-1978
		GR 64513 A1		09-04-1980
		IE 43956 B1		15-07-1981
		IL 50632 A		30-11-1979
		LU 76011 A1		25-05-1977
		MX 6821 E		06-08-1986
		MX 7114 E		29-06-1987
		NL 7611394 A ,B,		18-04-1977
		NO 763480 A ,B,		15-04-1977
		NO 771952 A ,B,		15-04-1977
		NO 813710 A ,B,		15-04-1977
		NZ 182270 A		28-07-1978
		PH 12507 A		18-04-1979
		PH 20254 A		10-11-1986
		PT 65708 A ,B		01-11-1976

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4072746	A	SE 430335 B SE 7611376 A SE 441744 B SE 8102022 A US 4225715 A US 4107315 A US 4137233 A US 4199586 A ZA 7606042 A	07-11-1983 22-06-1977 04-11-1985 30-03-1981 30-09-1980 15-08-1978 30-01-1979 22-04-1980 28-09-1977
US 4313951	A 02-02-1982	AT 379387 B AT 578080 A CA 1143736 A1 CA 1155852 A2 CH 649535 A5 DE 3044568 A1 DK 501180 A ,B, EG 14983 A ES 8302661 A1 ES 8301920 A3 FI 803652 A ,B, FI 854740 A ,B, FR 2470124 A1 FR 2553767 A1 GB 2065642 A ,B GB 2131421 A ,B GR 71608 A1 HK 31189 A HK 83090 A IE 50632 B1 IL 61501 A IL 69847 A IT 1148740 B KR 8500025 B1 KR 8500317 B2 KR 8500632 B2 LU 82957 A1 MX 158257 A NL 970028 I1 NL 8006399 A ,B, NO 803550 A ,B, NO 854001 A NO 156127 B NZ 195564 A PH 22629 A PT 72106 A ,B SE 442398 B SE 8008252 A US 4365065 A AT 379386 B AT 95983 A AU 551627 B2 AU 2475384 A AU 536354 B2 AU 6455780 A BE 886336 A1 JP 1639011 C JP 2050903 B	27-12-1985 15-05-1985 29-03-1983 25-10-1983 31-05-1985 27-08-1981 27-05-1981 31-12-1985 16-04-1983 01-04-1983 27-05-1981 29-11-1985 29-05-1981 26-04-1985 01-07-1981 20-06-1984 17-06-1983 21-04-1989 19-10-1990 28-05-1986 29-06-1984 29-06-1984 03-12-1986 11-02-1985 20-03-1985 06-05-1985 04-06-1981 18-01-1989 01-10-1997 16-06-1981 27-05-1981 27-05-1981 21-04-1987 30-09-1983 28-10-1988 01-12-1980 23-12-1985 27-05-1981 21-12-1982 27-12-1985 15-05-1985 08-05-1986 05-07-1984 03-05-1984 04-06-1981 25-05-1981 31-01-1992 05-11-1990

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
**PCT/JP2004/016193**

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 4313951	A	JP	60214776 A JP 1391523 C	28-10-1985 23-07-1987